<SEC-DOCUMENT>0001140361-23-025750.txt : 20230519
<SEC-HEADER>0001140361-23-025750.hdr.sgml : 20230519
<ACCEPTANCE-DATETIME>20230519162020
ACCESSION NUMBER:		0001140361-23-025750
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20230519
DATE AS OF CHANGE:		20230519
EFFECTIVENESS DATE:		20230519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272088
		FILM NUMBER:		23940383

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>ny20009120x1_s3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20009120x1_s3asr_200-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on May 19, 2023</div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195; </div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 8pt; text-align: center;">UNITED STATES<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt;">WASHINGTON, D.C. 20549</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">FORM S-3<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt;">REGISTRATION STATEMENT</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt;">UNDER</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt;">THE SECURITIES ACT OF 1933</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">INSMED INCORPORATED<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt; font-weight: normal;">(Exact name of Registrant as specified in its charter)</font></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 53.33%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Virginia </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">54-1972729 </div></td></tr><tr><td style="width: 53.33%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">of incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">700 US Highway 202/206<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(908) 977-9900<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">William H. Lewis<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chief Executive Officer<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">700 US Highway 202/206<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(908) 977-9900<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Copies to:</div></td></tr><tr><td style="width: 53.33%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Michael A. Smith <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">General Counsel <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">700 US Highway 202/206 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(908) 977-9900</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Michael J. Riella <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Covington &amp; Burling LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">One CityCenter <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">850 Tenth Street, NW <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Washington, DC 20001 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(202) 662-6000</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">Approximate date of commencement of proposed sale to the public:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">From time to time after this registration statement becomes effective.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: &#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box: &#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 20%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer &#x2612; </div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.89%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td></tr><tr><td style="width: 20%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.89%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_201-note_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXPLANATORY NOTE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This registration statement contains three prospectuses:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a base prospectus, which covers the offering, issuance (where applicable) and sale, by us or any selling securityholder, from time to time, of an indeterminate amount of our common stock and debt securities in one or more offerings at indeterminate prices&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a sales agreement prospectus, which covers the offering, issuance and sale of up to $215,585,139 of our common stock that may be issued and sold under a sales agreement, dated as of February&#160;25, 2021, with SVB Leerink LLC (now known as SVB Securities LLC); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a resale prospectus, which covers the resale, from time to time, of up to 27,793 shares of our common stock by the selling securityholder named therein.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus, and the resale prospectus immediately follows the sales agreement prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The $215,585,139 of shares of common stock that may be offered, issued and sold by us under the sales agreement prospectus, and the 27,793 shares of common stock that may be offered and sold by the selling securityholder under the resale prospectus, are included in the securities that may be offered, issued and sold under the base prospectus.</div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009120x1_s3asr_202-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROSPECTUS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 83px; width: 244px;" src="logo_insmed.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Common Stock<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Debt Securities</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We or any selling securityholder may from time to time offer to sell the securities identified above in amounts, at prices and on terms determined at the time of the offering and described in one or more supplements to this prospectus. Each time we or any selling securityholders sell securities pursuant to this prospectus, the specific terms and any other information relating to a specific offering and, if applicable, the selling securityholders, will be set forth in a prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our securities may be offered and sold in the same offering or in separate offerings to or through one or more underwriters, dealers, and agents, directly to purchasers, or through a combination of these methods. The names and compensation of any underwriter, dealer or agent involved in the sale of our securities will be described in the applicable prospectus supplement. See &#8220;Plan of Distribution&#8221; on page <a href="#tPOD">20</a> of this prospectus for additional information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;INSM.&#8221; The last reported sale price for our common stock on The Nasdaq Global Select Market on May 18, 2023 was $18.82. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807, and our telephone number is (908) 977-9900.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 15.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our securities involves a high degree of risk. You should carefully consider the risk factors incorporated in this prospectus by reference and described under the heading &#8220;Risk Factors&#8221; on page <a href="#tRF">3</a> of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">The date of this prospectus is May 19, 2023.</div></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_203-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tII">INSMED INCORPORATED<font style="padding-left: 1.75pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tII"><font style="padding-left: 5pt;">2</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">3</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNRF">NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 3.7pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNRF"><font style="padding-left: 5pt;">4</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP"><font style="padding-left: 5pt;">7</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC">DESCRIPTION OF COMMON STOCK<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC"><font style="padding-left: 5pt;">8</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOD">DESCRIPTION OF DEBT SECURITIES<font style="padding-left: 4.16pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOD">10</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSS">SELLING SECURITYHOLDERS<font style="padding-left: 4.53pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSS">19</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">20</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">21</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">21</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">21</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">INCORPORATION BY REFERENCE<font style="padding-left: 1.57pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">22</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_204-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is part of a registration statement that we filed with the SEC, utilizing a &#8220;shelf&#8221; registration process as a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 under the Securities Act of 1933 (the &#8220;Securities Act&#8221;). Under this shelf registration process, we and any selling securityholders may offer and sell from time to time in one or more offerings the securities described in this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus provides you with a general description of our securities. Each time we or any selling securityholders sell securities pursuant to this prospectus, we and the selling securityholders will provide a prospectus supplement, which will be delivered with this prospectus, that will contain specific information about the offering and the terms of the particular securities offered. The prospectus supplement, or information incorporated by reference in this prospectus or any prospectus supplement that is of a more recent date, may also add to, update or change information contained in this prospectus. To the extent that any statement that we or any selling securityholders make in a prospectus supplement or incorporate by reference from a future SEC filing is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement or such incorporated document. This prospectus may not be used to consummate a sale of our securities unless it is accompanied by a prospectus supplement. We and the selling securityholders may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to an offering of our securities. You should carefully read this prospectus, any applicable prospectus supplement and any relevant free writing prospectus, together with the information incorporated herein by reference, prior to making any decision regarding an investment in our securities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have not, and no selling securityholder has, authorized anyone to provide you with different or additional information from that contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any information that others may give. We are not, and no selling securityholder is, making offers to sell or seeking offers to buy our securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of the respective dates of such documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the context otherwise indicates, references in this prospectus to &#8220;Insmed&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated, a Virginia corporation, together with its consolidated subsidiaries. Insmed, PULMOVANCE, ARIKARES and ARIKAYCE are trademarks of Insmed Incorporated. Our logos and trademarks are the property of Insmed. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217; trademarks or trade dress in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_204-about_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tII"><!--Anchor--></a>INSMED INCORPORATED</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We were incorporated in the Commonwealth of Virginia on November&#160;29, 1999. On December&#160;1, 2010, we completed a business combination with Transave, Inc., a privately held New Jersey based company focused on the development of differentiated and innovative inhaled pharmaceuticals for the site specific treatment of serious lung diseases.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our first commercial product, ARIKAYCE, is approved in the United States (the &#8220;U.S.&#8221;) as ARIKAYCE&#174; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the U.S. in September 2018 for the treatment of <font style="font-style: italic;">Mycobacterium avium</font> complex (&#8220;MAC&#8221;) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission approved ARIKAYCE for the treatment of nontuberculous mycobacterial (&#8220;NTM&#8221;) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (&#8220;CF&#8221;). In March 2021, Japan&#8217;s Ministry of Health, Labour and Welfare approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our clinical-stage pipeline includes brensocatib, treprostinil palmitil inhalation powder (&#8220;TPIP&#8221;) and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase&#160;1, which we are developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps. TPIP is an inhaled formulation of the treprostinil prodrug trespostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. Our early-stage research programs encompass a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807, and our telephone number is (908) 977-9900. Our Internet address is www.insmed.com. The information on our web site is not incorporated by reference into this prospectus or any applicable prospectus supplement and should not be considered to be part of this prospectus or any applicable supplement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_205-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An investment in our securities involves risks. Prior to making a decision about investing in our securities, you should carefully consider the specific risks discussed under &#8220;Risk Factors&#8221; in our Annual Report on Form&#160;10-K for our most recent fiscal year, as updated by our Quarterly Reports on Form 10-Q and other SEC filings subsequent thereto, pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and in any applicable prospectus supplement. The risks and uncertainties described in any applicable prospectus supplement and in our SEC filings are not the only ones we face. Each of these risks could materially and adversely affect our business, financial condition, results of operations and prospects, resulting in a complete or partial loss of your investment.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_206-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tNRF"><!--Anchor--></a>NOTE REGARDING FORWARD-LOOKING STATEMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains, and the information incorporated by reference herein and any applicable prospectus supplement may contain, forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements,&#8221; as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully commercialize ARIKAYCE, our only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner complete the study to validate a patient reported outcome tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability of us, PARI Pharma GmbH or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira&#174; Nebulizer System (&#8220;Lamira&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, or our other product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_206-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, or for our product candidates in the US, Europe, Japan or other markets, including separate regulatory approval for Lamira in each market and for each usage;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to attract and retain key personnel or to effectively manage our growth;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our acquired technologies, products and product candidates are not commercially successful;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adapt to our highly competitive and changing environment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that we are unable to maintain our significant customers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that government healthcare reform materially increases our costs and damages our financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impact of the COVID-19 pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI Pharma GmbH and AstraZeneca AB, and failure to comply with our obligations under such agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our limited experience operating internationally;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our history of operating losses, and the possibility that we never achieve or maintain profitability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">goodwill impairment charges affecting our results of operations and financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_206-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this prospectus and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for our most recent fiscal year, as updated from time to time in our Quarterly Reports on Form 10-Q and other SEC filings subsequent thereto, including any applicable prospectus supplement. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in such forward-looking statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this prospectus, the registration statement of which this prospectus forms a part, any applicable prospectus supplement, and the documents incorporated by reference herein and therein, in their entirety and with the understanding that our actual future results may be materially different from those expressed in forward-looking statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_207-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will retain broad discretion over the use of the net proceeds from the sale of our securities offered under this prospectus. Unless we indicate otherwise in the applicable prospectus supplement, we anticipate that any net proceeds will be used for working capital and general corporate purposes. We will not receive proceeds from sales of securities by selling securityholders except as otherwise stated in an applicable prospectus supplement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOC"><!--Anchor--></a>DESCRIPTION OF COMMON STOCK</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the material terms of our common stock, which is based upon, and is qualified in its entirety by reference to, our Articles of Incorporation, as amended (the &#8220;Articles of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and applicable provisions of the Virginia Stock Corporation Act (&#8220;VSCA&#8221;). This summary may not contain all the information that is important to you; you can obtain additional information regarding our Articles of Incorporation and Bylaws by referring to such documents, copies of which are included as exhibits to the registration statement of which this prospectus forms a part.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">General</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our Articles of Incorporation, we have authority to issue 500,000,000 shares of common stock, par value $0.01 per share. As of March&#160;14, 2023, there were 136,428,466 shares of common stock issued and outstanding. All shares of common stock will, when issued pursuant to this prospectus, be duly authorized, fully paid and nonassessable.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Dividend Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the rights of the holders of any of our preferred stock then outstanding, the holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this prospectus, we have not declared or paid any dividends on our shares of common stock, and there were no shares of preferred stock outstanding, although our board of directors is authorized to issue preferred stock with rights senior to those of the common stock without any further vote or action by the holders of our common stock.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Rights Upon Liquidation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of common stock will receive distributions pro&#160;rata out of assets that we can legally use to pay distributions, subject to the rights of the holders of any of our preferred stock then outstanding.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock are entitled to one vote per share and will have the exclusive power to vote on all matters presented to our shareholders, including the election of directors, except as otherwise provided by the VSCA and subject to the rights of the holders of any of our preferred stock then outstanding. An election of directors by our shareholders will be determined by a plurality of the votes cast by the shareholders entitled to vote on the election, although we have a director resignation policy applicable to director nominees in uncontested elections. Our Articles of Incorporation do not provide for cumulative voting. In accordance with our Articles of Incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year at our annual meeting of shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to certain exceptions set forth in the VSCA, matters other than the election of directors generally will be approved if the votes cast by our shareholders favoring the action exceed the votes cast opposing the action. Subject to the rights of the holders of any of our preferred stock then outstanding, however, the affirmative vote of at least 75% of the voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single group, will be required to take the following actions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">remove a director, which may only be done for cause; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">alter, amend, repeal, or adopt any provision inconsistent with, the provisions of (1) our Articles of Incorporation that provide for a classified board, director removal only for cause, filling of newly created or vacant directorships, or bylaw amendments or (2) our Bylaws.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Other Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock will have no preference, appraisal or exchange rights, except for any appraisal rights provided by the VSCA. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Potential Anti-Takeover Effects of Certain Provisions of Virginia Law and Our Organizational Documents </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain provisions of the VSCA, our Articles of Incorporation and our Bylaws could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The requirement that shareholders provide advance notice when nominating director candidates to serve on our board of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inability of shareholders to convene a shareholders&#8217; meeting without the chair of the board, the president or a majority of the board of directors first calling the meeting.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, LLC. Its address is 1717 Arch Street, Suite 1300, Philadelphia, PA 19103.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;INSM.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOD"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, debt securities, including debentures, notes, bonds and other evidences of indebtedness as set forth in the applicable prospectus supplement. The debt securities will be our direct obligations, either secured or unsecured, and may include convertible debt securities. The debt securities may be our senior, senior subordinated or subordinated obligations. The debt securities will be issued under an indenture between us and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as trustee, which we may amend or supplement from time to time. This prospectus, together with the applicable prospectus supplement, will describe the terms of a particular series of debt securities that we may offer from time to time. The indenture has been qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summary of the material provisions of the indenture and the debt securities does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the provisions of the indenture and certificate evidencing the applicable debt securities. Therefore, you should carefully consider the indenture that is filed as an exhibit to the registration statement that includes this prospectus. Other specific terms of the indenture and debt securities will be described in the applicable prospectus supplement. If any particular terms of the indenture or debt securities described in a prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus supplement. In this description of the debt securities, the words &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer only to Insmed Incorporated and not to our subsidiaries, unless we otherwise expressly state or the context otherwise requires.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Debt securities may be issued in one or more series without limitation as to aggregate principal amount. We&#160;may specify a maximum aggregate principal amount for the debt securities of any series. We are not limited as to the amount of debt securities that we may issue under the indenture. The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. The prospectus supplement relating to a particular series of debt securities will set forth the material terms of the debt securities being offered, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title of the debt securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the offering price; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any limit on the aggregate principal amount that may be issued; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the person to whom any interest on a debt security will be payable, if other than the person in whose name that debt security is registered at the close of business on the record date for such interest; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date or dates on which the principal of any debt securities is payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the interest rate or rates (which may be fixed or variable) at which the debt securities will bear interest, if any, the date or dates from which any such interest will accrue, the interest payment dates on which any such interest will be payable and the record date for any such interest payable on any interest payment date (or the method of determining the dates or rates); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the place or places where the principal of and any premium and interest on the debt securities will be payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the period or periods within which, the price or prices at which and the terms and conditions upon which the debt securities may be redeemed, in whole or in part, at our option and, if other than by a resolution of the board of directors, the manner in which any election by us to redeem the debt securities will be evidenced;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the obligation, if any, of ours to redeem or repurchase the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder and the period or periods within which, the price or prices at which and the terms and conditions upon which the debt securities will be redeemed or repurchase, in whole or in part, pursuant to such obligation; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if other than in denominations of $1,000 or any integral multiple thereof, the denominations in which the debt securities will be issuable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the amount of principal of or any premium or interest on the debt securities may be determined with reference to an index or pursuant to a formula, the manner in which such amounts will be determined; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if other than U.S. currency, the currency, currencies or currency units in which the principal of or any premium or interest on the debt securities will be payable and the manner of determining the equivalent thereof in U.S. currency for any purpose, and whether we or a holder may elect payment to be made in a different currency; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the principal of or any premium or interest on the debt securities is to be payable, at our election or the election of a holder, in one or more currencies or currency units other than that or those in which such debt securities are stated to be payable, the currency, currencies or currency units that the principal of or any premium or interest on such debt securities as to which such election is made will be payable, the periods within which and the terms and conditions upon which such election is to be made and the amount so payable (or the manner in which such amount will be determined);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if other than the entire principal amount thereof, the portion of the principal amount of the debt securities that will be payable upon declaration of acceleration of maturity thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the principal amount payable at stated maturity of the debt securities will not be determinable as of any one or more dates prior to stated maturity, the amount which will be deemed to be the principal amount of such debt securities as of any such date for any purpose, including the principal amount thereof that will be due and payable upon maturity other than the state maturity or that will be deemed to be outstanding as of any date prior to the stated maturity (or, in each case, the manner that such amount deemed to be the principal amount will be determined); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, whether the debt securities will be subject to the defeasance provisions described below under &#8220;Satisfaction and Discharge; Defeasance&#8221; or such other defeasance provisions specified in the applicable prospectus supplement for the debt securities and, if other than by a resolution of the board of directors, the manner in which any election by us to defease such debt securities will be evidenced; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the terms of any right or obligation to convert or exchange debt securities, including, if applicable, the conversion or exchange rate or price, the conversion or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of a holder or at our option, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such debt securities are redeemed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether or not the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the forms of the debt securities and whether the debt securities will be issuable in whole or in part in the form of one or more global securities, and if so, the respective depositaries for such global securities, the form of any legend or legends that will be borne by any such global securities in addition to or in lieu of that set forth in the indenture and any circumstances in addition to or in lieu of those set forth in the indenture in which any such global security may be exchanged in whole or in part for debt securities registered, and any transfer of such global security in whole or in part may be registered, in the name or names of the persons other than the depositary for such global security or a&#160;nominee thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any deletion of, addition to or change in the events of default which applies to the debt securities and any change in the right of the trustee or the requisite holders of such debt securities to declare the principal amount thereof due and payable pursuant to the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any deletion of, addition to or change in the covenants set forth in the indenture which apply to the debt securities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any authenticating agents, paying agents, security registrars or such other agents necessary in connection with the issuance of the debt securities, including exchange rate agents and calculations agents; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, any terms of any security provided for the debt securities, including any provisions regarding the circumstances under which collateral may be released or substituted; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the terms of any guaranties for the debt securities and any circumstances under which there may be additional obligors on the debt securities; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other terms of such debt securities.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies, or if the principal of or premium, if any, or interest on any series of debt securities is payable in a foreign currency or currencies, we will include in the applicable prospectus supplement information on the restrictions, elections, material federal income tax considerations, specific terms and other information with respect to that issue of debt securities and the foreign currency or currencies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise specified in the applicable prospectus supplement, the debt securities will be registered debt securities. Debt securities may be sold at a substantial discount below their stated principal amount, bearing no interest or interest at a rate which at the time of issuance is below market rates. The U.S. federal income tax considerations applicable to debt securities sold at a discount will be described in the applicable prospectus supplement. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Exchange and Transfer </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Debt securities may be transferred or exchanged at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will not impose a service charge for any transfer or exchange, but we may require holders to pay any tax or other governmental charges associated with any transfer or exchange. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of any partial redemption of debt securities of any series, we will not be required to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issue, register the transfer of or exchange any debt security of that series during a period beginning at the opening of business 15 days before the day of sending a notice of redemption and ending at the close of business on the day of sending such notice; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except the unredeemed portion being redeemed in part.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Initially, we will appoint the trustee as the security registrar. Any transfer agent, in addition to the security registrar initially designated by us, will be named in the applicable prospectus supplement. We may designate additional transfer agents or change transfer agents or change the office of the transfer agent. However, we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Global Securities </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The debt securities of any series may be represented, in whole or in part, by one or more global securities. Each global security will: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be registered in the name of a depositary, or its nominee, that we will identify in a prospectus supplement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be delivered to the depositary or nominee or custodian; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">bear any required legends; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">constitute a single debt security.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No global security may be exchanged in whole or in part for debt securities registered in the name of any person other than the depositary or any nominee unless: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the depositary has notified us that it is unwilling or unable to continue as depositary or has ceased to be qualified to act as depositary; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an event of default has occurred and is continuing with respect to the debt securities of the applicable series; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other circumstance described in the applicable prospectus supplement has occurred permitting or requiring the issuance of any such security.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Conversion or Exchange </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any debt securities being offered are convertible into or exchangeable for our common stock or other securities, the relevant prospectus supplement will set forth the terms of conversion or exchange. Those terms will include, as applicable, the conversion or exchange price or rate, the conversion or exchange period, provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option, the number of shares of common stock or other securities, or the method of determining the number of shares of common stock or other securities, to be received by the holder upon conversion or exchange, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such series of debt securities are redeemed. These provisions may allow or require the number of shares of our common stock or other securities to be received by the holders of such series of debt securities to be adjusted. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Payment and Paying Agents </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated in the prospectus supplement applicable to a series of debt securities, the provisions described in this paragraph will apply to the debt securities. Payment of interest on a debt security on any interest payment date will be made to the person in whose name the debt security is registered at the close of business on the regular record date. Payment on debt securities of a particular series will be payable at the office of a paying agent or paying agents designated by us. However, at our option, we may pay interest by mailing a check or by wire transfer to the record holder. The trustee will be designated as our initial paying agent. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also name any other paying agents in the prospectus supplement applicable to a series of debt securities. We may designate additional paying agents, change paying agents or change the office of any paying agent. However, we will be required to maintain a paying agent in each place of payment for the debt securities of a particular series. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All moneys paid by us to a paying agent for payment on any debt security that remain unclaimed for a&#160;period ending the earlier of: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">10 business days prior to the date the money would be turned over to the applicable state; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at the end of two years after such payment was due, will be repaid to us thereafter. The holder may look only to us for such payment.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">No Protection in the Event of a Change of Control </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction, whether or not such transaction results in a change in control. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Covenants </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will set forth in the prospectus supplement any financial or restrictive covenants applicable to any issue of a particular series of debt securities. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Consolidation, Merger and Sale of Assets </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, we may not consolidate with or merge into any other person, in a transaction in which we are not the surviving corporation, or sell, convey, transfer or lease all or substantially all our properties and assets to, any entity, unless:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the successor entity, if any, is a corporation, limited liability company, partnership, trust or other business entity existing under the laws of the United States, any State within the United States or the District of Columbia; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the successor entity assumes our obligations under the debt securities and the applicable indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain other conditions specified in the indenture are met regarding our delivery of our officer&#8217;s certificate and opinion of counsel to trustee. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into, sell or transfer all or part of its properties to us. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Events of Default </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we indicate otherwise in a prospectus supplement with respect to a particular series of debt securities, the following will be events of default for any series of debt securities under the indenture:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we fail to pay any interest on any debt security of that series when it becomes due and we subsequently fail to pay such interest for 30 days; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we fail to pay principal of or any premium on any debt security of that series when due; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we fail to perform, or breach, any other covenant or warranty in the applicable indenture and such failure continues for 90 days after we are given the notice required in the indenture; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain bankruptcy, insolvency or reorganization events with respect to us.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional or different events of default applicable to a series of debt securities may be described in the prospectus supplement for that series. An event of default for one series of debt securities is not necessarily an event of default for any other series of debt securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Within 90 days after the occurrence of any default under the indenture with respect to the debt securities of any series that is known to a responsible officer of the trustee, the trustee will give the holders of the debt securities of such series notice of such default as and to the extent provided by the Trust Indenture Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trustee may withhold notice to the holders of any default, except defaults in the payment of principal, premium, if any, interest, any sinking fund installment on, or with respect to any conversion right of, the debt securities of such series. However, the trustee must consider it to be in the interests of the holders of the debt securities of such series to withhold this notice. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we indicate otherwise in a prospectus supplement, if an event of default, other than an event of default described in clause (4) above, shall occur and be continuing with respect to any series of debt securities, either the trustee or the holders of at least 25% in aggregate principal amount of the outstanding securities of that series may declare the principal amount and premium, if any, of the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, to be due and payable immediately. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an event of default described in clause (4) above shall occur, the principal amount and premium, if any, of all the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, will automatically become immediately due and payable without any declaration or other action on the part of the trustee or any holder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After acceleration, the holders of a majority in aggregate principal amount of the outstanding securities of that series may, under certain circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal, or other specified amounts or interest, have been cured or waived. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other than the duty to act as a prudent person during an event of default, the trustee will not be obligated to exercise any of its rights or powers at the request of the holders unless the holders shall have offered to the trustee indemnity reasonably satisfactory to it. Generally, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A holder of debt securities of any series will not have any right to institute any proceeding under the indenture, or for the appointment of a receiver or a trustee, or for any other remedy under the indenture, unless: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holder has previously given to the trustee written notice of a continuing event of default with respect to the debt securities of that series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holders of at least a majority in aggregate principal amount of the outstanding debt securities of </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">that series have made a written request to the trustee and have offered to the trustee security or indemnity reasonably satisfactory to the trustee to institute the proceeding; and </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the trustee has failed to institute the proceeding and has not received direction inconsistent with the original request from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series within 60 days after the original request.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders may, however, sue to enforce the payment of principal, premium or interest on any debt security on or after the due date or to enforce the right, if any, to convert any debt security (if the debt security is convertible) without following the procedures listed in clauses (1) through (3) immediately above. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent any debt securities are outstanding, we will furnish the trustee an annual statement as to whether or not we are in default in the performance of the conditions and covenants under the indenture and, if so, specifying all known defaults. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Modification and Waiver </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we indicate otherwise in a prospectus supplement, we and the applicable trustee may make modifications and amendments to an indenture with the consent of the holders of a majority in aggregate principal amount of the outstanding securities of each series affected by the modification or amendment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also make modifications and amendments to the indenture for the benefit of holders without their consent, for certain purposes including, but not limited to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">providing for our successor to assume the covenants under the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adding covenants and/or events of default; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">making certain changes to facilitate the issuance of the debt securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">securing the debt securities, including provisions relating to the release or substitution of collateral; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">providing for guaranties of, or additional obligors on, the debt securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">providing for a successor trustee or additional trustees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">curing any ambiguities, defects or inconsistencies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conforming the terms to the description of the terms of the securities in an offering memorandum, prospectus supplement or other offering document; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other changes that do not adversely affect the rights or interest of any holder;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">complying with the requirements of the SEC in order to effect or maintain the qualification of the Indenture under the Trust Indenture Act; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">complying with the applicable procedures of the applicable depositary.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">However, neither we nor the trustee may make any modification or amendment without the consent of the holder of each outstanding debt security affected by the modification or amendment if such modification or amendment would: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">change the stated maturity of any debt security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduce the principal, premium, if any, or interest on any debt security or any amount payable upon redemption or repurchase, whether at our option or the option of any holder, or reduce the amount of any sinking fund payments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduce the principal of an original issue discount security or any other debt security payable on acceleration of maturity; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">change the currency in which any debt security is payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impair the right to enforce any payment after the stated maturity or redemption date of such debt security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduce the percentage in principal amount of outstanding securities of any series required for the consent of holders for any supplemental indenture or for any waiver provided for in the indenture;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adversely affect the right to convert any debt security if the debt security is a convertible debt security; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">change the provisions in the indenture that relate to modifying or amending the indenture, except to increase any such percentage or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of each outstanding debt security affected thereby.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of not less than a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a default in the payment of the principal of or any premium or interest on any debt security of that series as and when the same will become due and payable by the terms thereof, otherwise than by acceleration; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in respect of a covenant or provision of the Indenture which cannot be modified or amended without the consent of the holder of each outstanding security of such series affected by such default.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Satisfaction and Discharge; Defeasance </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may be discharged from our obligations under the debt securities of any series that have matured or will mature or be redeemed within one year, subject to limited exceptions, if we deposit enough money with the trustee to pay all of the principal, interest and any premium due to the stated maturity date or redemption date of the debt securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture contains a provision that permits us to elect either or both of the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We may elect to be discharged from all of our obligations, subject to limited exceptions, with respect to any series of debt securities then outstanding. If we make this election, the holders of the debt securities of the series will not be entitled to the benefits of the indenture, except for the rights of holders to receive payments on debt securities or the registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We may elect to be released from our obligations under some or all of any financial or restrictive covenants applicable to the series of debt securities to which the election relates and from the consequences of an event of default resulting from a breach of those covenants.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To make either of the above elections, we must irrevocably deposit in trust with the trustee enough money to pay in full the principal, interest and premium on the debt securities and satisfy certain other conditions described in the indenture. This amount may be deposited in cash and/or U.S. government obligations or, in the case of debt securities denominated in a currency other than U.S. dollars, cash in the currency in which such series of securities is denominated and/or foreign government obligations. As one of the conditions to either of the above elections, for debt securities denominated in U.S. dollars, we must deliver to the trustee an opinion of counsel that the holders of the debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the action. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Foreign government obligations&#8221; means, with respect to debt securities of any series that are denominated in a currency other than United States dollars: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">direct obligations of the government that issued or caused to be issued the currency in which such securities are denominated and for the payment of which obligations its full faith and credit is pledged, or, with respect to debt securities of any series which are denominated in euros, direct obligations of certain members of the European Union for the payment of which obligations the full faith and credit of such members is pledged, which in each case are not callable or redeemable at the option of the issuer thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obligations of a person controlled or supervised by or acting as an agency or instrumentality of a government described in the bullet above, the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by such government, which are not callable or redeemable at the option of the issuer thereof; or </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any depository receipt issued by a bank as custodian with respect to any obligation specified in the first&#160;two bullet points and held by such bank for the account of the holder of such deposit any receipt, or with respect to any such obligation which is so specified and held.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;U.S. government obligations&#8221; means:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any security which is:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a direct obligation of the United States of America for the payment of which the full faith and credit of the United States of America is pledged, which is not callable or redeemable at the option of the issuer thereof or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an obligation of a person controlled or supervised by or acting as an agency or instrumentality of the United States of America the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States of America, which is not callable or redeemable at the option of the issuer thereof; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any depository receipt issued by a bank as custodian with respect to any U.S. government obligation specified in the two bullet points above and held by such bank for the account of the holder of such deposit any receipt, or with respect to any specific payment of principal of or interest on any U.S.&#160;government obligation which is so specified and held, provided that (except&#160;as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. government obligation or the specific payment of principal or interest evidenced by such depositary receipt.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Notices </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notices to holders will be delivered in person, mailed by first-class mail (registered or certified, return receipt requested), sent by facsimile transmission, email or overnight air courier guaranteeing next day delivery. If any debt securities are in the form of global securities, notices will be sent in accordance with the applicable rules and procedures of the depositary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Governing Law; Wavier of Jury Trial; Jurisdiction</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture and the debt securities will be governed by, and construed under, the laws of the State of New York. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture, the securities or the transactions contemplated thereby may be instituted in the Federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document by any method permitted under the indenture (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">No Personal Liability of Directors, Officers, Employees and Shareholders </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No incorporator, shareholder, employee, agent, officer, director or subsidiary of ours will have any liability for any obligations of ours, or because of the creation of any indebtedness, under the debt securities, the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_208-description_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">indenture, or in any board resolution, officer&#8217;s certificate or supplemental indenture. The indenture provides that all such liability is expressly waived and released as a condition of, and as a consideration for, the execution of such indenture and the issuance of the debt securities. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Regarding the Trustee </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accompanying prospectus supplement will specify the trustee for the particular series of debt securities to be issued under the indenture. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture will limit the right of the trustee, should it become our creditor, to obtain payment of claims or secure its claims. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trustee is permitted to engage in certain other transactions with us. However, if the trustee acquires any conflicting interest, and there is a default under the debt securities of any series for which it is trustee, the trustee must eliminate the conflict or resign. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_209-security_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSS"><!--Anchor--></a>SELLING SECURITYHOLDERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our securities in various private transactions. Such selling securityholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their transferees, pledgees, donees or successors, all of whom we refer to as &#8220;selling securityholders,&#8221; may from time to time offer and sell the securities pursuant to this prospectus and any applicable prospectus supplement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The applicable prospectus supplement will set forth the name of each selling securityholder and the number of and type of securities beneficially owned by such selling securityholder that are covered by such prospectus supplement. The applicable prospectus supplement also will disclose whether any of the selling securityholders have held any position or office with, have been employed by or otherwise have had a material relationship with us during the three years prior to the date of the prospectus supplement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_210-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and any selling securityholders may sell the securities registered pursuant to this prospectus in the following ways:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through dealers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through agents;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">directly to purchasers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in at-the-market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act to or through an underwriter or underwriters acting as principal or agent;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through a combination of any of the foregoing methods; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through any other method described in the applicable prospectus supplement.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and any selling securityholders reserve the right to sell directly to or exchange our securities directly with investors on our own behalf in those jurisdictions where we are authorized to do so.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and any selling securityholders may distribute such securities from time to time in one or more transactions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at a fixed price or prices, which may be changed from time to time;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at market prices prevailing at the time of sale;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at prices related to such prevailing market prices; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at negotiated prices.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and any selling securityholders, or the purchasers of the securities for whom the underwriters may act as agents, may compensate underwriters in the form of underwriting discounts or commissions in connection with the sale of the securities. Underwriters may sell our securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agents. Unless otherwise indicated in the applicable prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase our securities as a principal and may then resell such securities at varying prices to be determined by the dealer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and any selling securityholders will name any underwriter, dealer or agent involved in the offer and sale of securities in the applicable prospectus supplement. In addition, we and any selling securityholders will describe in the applicable prospectus supplement the public offering or purchase price and the proceeds we and any selling securityholders will receive from the sale of our securities, any compensation we and any selling securityholders will pay to underwriters, dealers or agents in connection with such offering of our securities, any discounts, concessions or commissions allowed or re-allowed by underwriters to participating dealers, and any exchanges on which our securities will be listed. Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We and any selling securityholders may enter into agreements to indemnify underwriters, dealers and agents against certain civil liabilities, including liabilities under the Securities Act, and to reimburse these persons for certain expenses. We and any selling securityholders may also agree to contribute to payments that the underwriters, dealers or agents or any of their controlling persons may be required to make in respect of such liabilities. We and any selling securityholders may grant underwriters who participate in the distribution of the securities being registered pursuant to this prospectus an option to purchase additional securities in connection with a subsequent distribution. Certain underwriters, dealers or agents and their associates may engage in transactions with and perform services for us in the ordinary course of our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To facilitate the offering of our securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. Such transactions may include over-allotments or short sales of our securities, which involve the sale by persons participating in the offering of more securities than we and any selling securityholders sold to them. In these circumstances, these persons </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_210-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">would cover such over-allotments or short positions by making purchases in the open market or by exercising their option to purchase additional securities, if any. In addition, these persons may stabilize or maintain the price of our securities by bidding for or purchasing such securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. Should these transactions be undertaken, they may be discontinued at any time.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the applicable prospectus supplement indicates otherwise, the legality of the securities being offered by this prospectus will be passed upon for us by Covington &amp; Burling LLP, Washington, D.C. and/or Hunton Andrews Kurth LLP, Richmond, Virginia.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tEXP"><!--Anchor--></a>EXPERTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, and the effectiveness of our internal control over financial reporting as of December&#160;31, 2022, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s reports, given on their authority as experts in accounting and auditing.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public from the SEC&#8217;s website at www.sec.gov. We maintain a website at www.insmed.com. The information on our website is not incorporated by reference into this prospectus or any applicable prospectus supplement and should not be considered to be part of this prospectus or any applicable supplement. We have filed with the SEC a registration statement under the Securities Act with respect to the securities registered pursuant hereto. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. For further information with respect to us and the securities registered pursuant to this prospectus, you should review the registration statement, the applicable prospectus supplement, the information incorporated herein and therein, and the exhibits included herein and therein.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_210-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIBR"><!--Anchor--></a>INCORPORATION BY REFERENCE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring to those publicly available documents. The information that we incorporate by reference is considered to be part of this prospectus. We incorporate by reference the documents listed below (File No. 000-30739) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of this registration statement and, in the case of any particular offering of our securities, the date such offering is terminated:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450623000009/insm-20221231.htm">February&#160;23, 2023</a>;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2022 from our definitive proxy statement on Schedule 14A, as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123015322/ny20006571x1_def14a.htm">March&#160;31, 2023</a>;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450623000012/insm-20230331.htm">May&#160;4, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Current Report on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123024132/brhc20052827_8k.htm">May 11, 2023</a>; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Description of our common stock contained in our registration statement on <a href="https://www.sec.gov/Archives/edgar/data/1104506/000091664100000789/0000916641-00-000789-0001.txt">Form 8-A, dated June&#160;1, 2000</a>, as updated by the <a href="https://www.sec.gov/Archives/edgar/data/1104506/000110450621000005/insm20201231ex45.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a>, filed as Exhibit 4.5 to the Annual Report on Form 10-K for the year ended December&#160;31, 2020, and including any amendment or report subsequently filed for the purpose of updating such description.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and information that we subsequently file with the SEC will automatically update and supersede the information herein to the extent inconsistent herewith. This means that it is important to review all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference has been modified or superseded.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may request a copy of our SEC filings at no cost, by telephoning or writing us at the following telephone number or address:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Insmed Incorporated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">700 US Highway 202/206<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Michael A. Smith, General Counsel<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(908) 977-9900</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009120x1_s3asr_300-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">$215,585,139</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 83px; width: 244px;" src="logo_insmed.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Common Stock</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We previously entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with SVB Securities LLC, formerly known as SVB Leerink LLC (&#8220;SVB Securities&#8221;) dated February&#160;25, 2021, relating to shares of our common stock, par value $0.01 per share, offered by this prospectus. We originally filed a prospectus supplement, dated February&#160;25, 2021 (together with the applicable base prospectus, the &#8220;Prior Prospectus&#8221;), for the offer and sale of shares of our common stock having an aggregate offering price of up to $250,000,000 from time to time through SVB Securities, acting as our agent, pursuant to the Sales Agreement. As of the date of this prospectus, we have sold an aggregate of $34,414,861 million of shares of common stock pursuant to the Sales Agreement and the Prior Prospectus. The common stock available to be sold under the Prior Prospectus as of the date of this prospectus will no longer be offered and sold under the Prior Prospectus, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the offer and sale of up to $215,585,139 of shares of our common stock that may be sold under the Sales Agreement as of the date of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;INSM&#8221;. The last reported sale price of our common stock on the Nasdaq Global Select Market on May 18, 2023 was $18.82 per share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Sales of our common stock, if any, under this prospectus will be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). SVB Securities is not required to sell any specific number or dollar amount of shares of our common stock, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, or mutually agreed terms between SVB Securities and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The compensation payable to SVB Securities for sales of common stock pursuant to the Sales Agreement will be an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. See &#8220;Plan of Distribution&#8221; beginning on page <a href="#pPOD">14</a> for additional information regarding the compensation to be paid to SVB Securities. In connection with the sale of the common stock on our behalf, SVB Securities will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation paid to SVB Securities will be deemed to be underwriting commissions or discounts. We have also agreed in the Sales Agreement to provide indemnification and contribution to SVB Securities with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#pRF">8</a> of this prospectus and the documents incorporated by reference into this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 15.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">SVB Securities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; text-align: center;">Prospectus dated May 19, 2023</div></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_301-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Prospectus</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pATP"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pFLS">FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.89pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pFLS"><font style="padding-left: 5pt;">2</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pPSUM">PROSPECTUS SUMMARY<font style="padding-left: 2.84pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pPSUM"><font style="padding-left: 5pt;">5</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pTO">THE OFFERING<font style="padding-left: 2.85pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pTO"><font style="padding-left: 5pt;">6</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pRF"><font style="padding-left: 5pt;">8</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pUOP">10</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pDOC">DESCRIPTION OF COMMON STOCK<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pDOC"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pDIL">DILUTION<font style="padding-left: 1.74pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pDIL">13</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pPOD">14</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pLM">15</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pEXP">15</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pIOC">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE<font style="padding-left: 4.67pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#pIOC">16</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_302-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) using a shelf registration process. Under this shelf registration process, we may offer and sell shares of our common stock having an aggregate offering price of up to $215,585,139 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of the offering.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent the information contained in this prospectus differs or varies from the information contained in documents previously filed with the SEC that are incorporated by reference herein, the information in this prospectus will supersede such information. For a more detailed understanding of an investment in our common stock, you should read this prospectus, together with the information incorporated by reference herein and additional information described under the heading &#8220;Incorporation&#160;of Certain Documents by Reference&#8221; in this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Company nor SVB Securities has authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus and in any related free writing prospectus filed by us with the SEC. Accordingly, neither the Company nor SVB Securities takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. Neither the Company nor SVB Securities is making offers to sell or seeking offers to buy shares of our common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus, the documents incorporated by reference herein and any related free writing prospectus is accurate only as of the respective dates of such documents, regardless of the time of delivery of this prospectus or any sale of the common stock offered hereby. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the context otherwise indicates, references in this prospectus to &#8220;Insmed&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated, a Virginia corporation, together with its consolidated subsidiaries. INSMED and ARIKAYCE are trademarks of Insmed Incorporated. Our logos and trademarks are the property of Insmed. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217; trademarks or trade dress in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_303-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pFLS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the other documents that are incorporated herein by reference contain forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements&#8221;, as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act are statements that are not historical facts and involve a number of risks and uncertainties. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully commercialize ARIKAYCE, our only approved product, in the United States (&#8220;U.S.&#8221;), Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner complete the study to validate a patient reported outcome tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability of us, PARI Pharma GmbH (&#8220;PARI&#8221;) or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira Nebulizer System (&#8220;Lamira&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, treprostinil palmitil inhalation powder (&#8220;TPIP&#8221;) or our other product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_303-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, or for our product candidates in the U.S., Europe, Japan or other markets, including separate regulatory approval for Lamira in each market and for each usage;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to attract and retain key personnel or to effectively manage our growth; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our acquired technologies, products and product candidates are not commercially successful;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adapt to our highly competitive and changing environment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that we are unable to maintain our significant customers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that government healthcare reform materially increases our costs and damages our financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impact of the COVID-19 pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB, and failure to comply with our obligations under such agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our limited experience operating internationally;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our history of operating losses, and the possibility that we never achieve or maintain profitability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">goodwill impairment charges affecting our results of operations and financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_303-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not actually achieve the results, plans, intentions or expectations indicated by our forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These risks and uncertainties include, but are not limited to, those described above, in the &#8220;Risk Factors&#8221; section of this prospectus, in the &#8220;Risk Factors&#8221; section of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in such forward-looking statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this prospectus and the documents incorporated by reference herein with the understanding that our actual future results may be materially different from those expressed in forward-looking statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009120x1_s3asr_304-sum_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pPSUM"><!--Anchor--></a>PROSPECTUS SUMMARY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary highlights selected information included or incorporated by reference in this prospectus and does not contain all of the information that may be important to you. You should carefully review this entire prospectus, including the risk factors and financial statements and related notes thereto included or incorporated by reference herein, before making a decision to purchase our common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the U.S. as ARIKAYCE&#174; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the U.S. in September 2018 for the treatment of <font style="font-style: italic;">Mycobacterium avium</font> complex (&#8220;MAC&#8221;) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission approved ARIKAYCE for the treatment of nontuberculous mycobacterial (&#8220;NTM&#8221;) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (&#8220;CF&#8221;). In March 2021, Japan&#8217;s Ministry of Health, Labour and Welfare approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our clinical-stage pipeline includes brensocatib, TPIP and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which we are developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps. TPIP is an inhaled formulation of the treprostinil prodrug trespostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. Our early-stage research programs encompass a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated in the Commonwealth of Virginia on November&#160;29, 1999. On December&#160;1, 2010, we completed a business combination with Transave, Inc., a privately held New Jersey-based company focused on the development of differentiated and innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. Our principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807, and our telephone number is (908) 977-9900. Our website address is www.insmed.com. The information on our website is not incorporated by reference into this prospectus and should not be considered to be part of this document.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009120x1_s3asr_304-sum_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pTO"><!--Anchor--></a>THE OFFERING</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common stock offered by us<font style="font-weight: normal; padding-left: 4.18pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Shares of our common stock having an aggregate offering price of up to $215,585,139 million. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common stock to be outstanding after this offering<font style="font-weight: normal; padding-left: 1.63pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Up to 147,884,324 shares of common stock (as more fully described in the notes following this table), assuming sales of 11,455,108 shares in this offering at a public offering price of $18.82 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on May 18, 2023. The actual number of shares issued will vary depending on how many shares of common stock we choose to sell and prices at which such sales occur. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Manner of offering<font style="font-weight: normal; padding-left: 4.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">&#8220;At the market&#8221; offering that may be made from time to time through our sales agent, SVB Securities LLC. See &#8220;Plan of Distribution&#8221; on page <a href="#pPOD">14</a> of this prospectus. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="font-weight: normal; padding-left: 1.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We intend to use the net proceeds we receive from this offering to fund activities related to the commercialization of ARIKAYCE, potential commercial launch of brensocatib, if approved, and further research and development of ARIKAYCE, brensocatib, TPIP, our early-stage research efforts or any of our product candidates, and for other general corporate purposes, including business expansion activities. See &#8220;Use of Proceeds&#8221; on page <a href="#pUOP">10</a> of this prospectus for additional information. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors<font style="font-weight: normal; padding-left: 5.3pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">An investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page&#160;<a href="#pRF">8</a> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider before deciding to invest in our common stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Nasdaq Global Select Market listing<font style="font-weight: normal; padding-left: 1.77pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;INSM&#8221;.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as otherwise indicated herein, the number of shares of our common stock to be outstanding immediately after this offering is based on 136,429,216 shares of our common stock outstanding as of March&#160;31, 2023. The number of shares of our common stock to be outstanding immediately after this offering excludes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">19,155,595 shares of our common stock issuable upon the exercise of stock options outstanding as of March&#160;31, 2023 at a weighted average exercise price of $21.74 per share&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">2,057,694 shares of our common stock issuable pursuant to unvested restricted stock units (&#8220;RSUs&#8221;) outstanding as of March&#160;31, 2023 at a weighted average grant price of $21.38; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">671,112 shares of our common stock issuable pursuant to unvested performance-based restricted stock units (&#8220;PSUs&#8221;) outstanding as of March&#160;31, 2023 at a weighted average grant price of $26.43;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">10,745,789 shares of our common stock reserved for issuance under our Amended and Restated 2019 Incentive Plan (the &#8220;Plan&#8221;), which reflects shares reserved under the Plan as of March&#160;31, 2023, as well as an additional 10,500,000 shares of common stock reserved after March&#160;31, 2023 in connection </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 34-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009120x1_s3asr_304-sum_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">with the adoption of the Plan (plus any shares subject to outstanding awards as of March&#160;31, 2023 under our 2017 Incentive Plan, 2015 Incentive Plan and 2013 Incentive Plan that subsequently are cancelled, terminated unearned, expired, forfeited, lapsed for any reason or are settled in cash without the delivery of shares)&#894;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,014,939 shares of our common stock reserved for issuance under our Employee Stock Purchase Plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,746,140 shares of our common stock reserved for issuance upon conversion of our 1.75% convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">17,692,290 shares of our common stock reserved for issuance upon conversion of our 0.75% convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">9,456,112 shares of our common stock reserved for issuance as acquisition consideration in connection with our acquisitions of Motus Biosciences, Inc., AlgaeneX, Inc. and Vertuis Bio, Inc.  </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 35-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_305-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pRF"><!--Anchor--></a>RISK FACTORS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An investment in our common stock involves significant risks. Before making an investment in our common stock, you should carefully read all of the information contained in this prospectus and in the documents incorporated by reference herein. For a discussion of risks that you should carefully consider before deciding to purchase any of our common stock, please review the risk factors disclosed below, together with the other information in this prospectus and the information and documents incorporated by reference herein, including the risk factors set forth in the &#8220;Risk Factors&#8221; section of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act. Any of these risks, as well as additional risks not currently known to us or that we currently deem immaterial, may adversely affect our business, financial condition, results of operations, and prospects, resulting in a decline in the trading price of our common stock and loss of all or part of your investment.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our management will have broad discretion over the actual amount and timing of the expenditures of the proceeds we receive in this offering and might not apply these proceeds in ways that enhance our financial condition or operating results or increase the value of your investment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to use the net proceeds we receive from this offering to fund activities related to the commercialization of ARIKAYCE, potential commercial launch of brensocatib, if approved, and further research and development of ARIKAYCE, brensocatib, TPIP, our early-stage research efforts or any of our product candidates, and for other general corporate purposes, including business expansion activities. This expected use of our net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amount and timing of our actual expenditures may vary significantly depending on numerous factors, the most significant of which are expenses related to our commercialization efforts for ARIKAYCE and brensocatib, if approved, expenses related to future ARIKAYCE, brensocatib and TPIP clinical trials, as well as any strategic transactions that we may enter into with third parties, and any unforeseen cash needs. Because of the number and variability of factors that will determine our use of the proceeds from this offering, their ultimate use may vary substantially from their currently intended use. As a result, our management will retain broad discretion over the allocation of the net proceeds we receive from this offering and could spend the proceeds in ways that do not necessarily improve our financial condition or operating results or enhance the value of our common stock and your investment therein. Additionally, until the net proceeds we receive are used, they may be placed in investments that do not produce income or that lose value. See &#8220;Use of Proceeds&#8221; for additional information.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">It is not possible to predict the aggregate proceeds resulting from sales made under the Sales Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to SVB Securities at any time throughout the term of the Sales Agreement. The number of shares that are sold through SVB Securities after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period, any limits we may set with SVB Securities in any applicable placement notice and the demand for our common stock. Because the price per share of each share sold pursuant to the Sales Agreement will fluctuate over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the Sales Agreement.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The common stock offered hereby will be sold in &#8220;at the market offerings&#8221; and investors who buy shares at different times will likely pay different prices.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If you purchase our common stock in this offering, you may incur immediate and substantial dilution in the book value of your shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The offering price per share of common stock in this offering may exceed the net tangible book value per&#160;share of our common stock outstanding prior to this offering. Therefore, if you purchase common stock in this offering, you may pay a price per share that exceeds our as adjusted net tangible book value per share of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 36-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_305-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">common stock. Assuming that an aggregate of 11,187,604 shares of our common stock are sold at an assumed offering price of $19.27 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on May 15, 2023, for aggregate gross proceeds of $215,585,139 million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $19.54 per share, representing the difference between our as adjusted net tangible book value per share as of March&#160;31, 2023, after giving effect to this offering, and the assumed offering price. Further dilution of your investment will result from, among other things, future equity issuances by us, the future exercise of stock options, vesting of RSUs and PSUs, conversion of some or all of our 2025 Notes and our 2028 Notes, to the extent we deliver shares upon conversion, and issuance of shares in connection with our acquisitions. See &#8220;Dilution&#8221; for a more detailed description of the dilution investors purchasing shares of our common stock in the offering will incur. Because the sales of the shares offered hereby will be made directly into the market, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing stockholders, will experience significant dilution if we sell shares at prices significantly below the price at which they invested.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 37-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_305-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pUOP"><!--Anchor--></a>USE OF PROCEEDS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue and sell shares of our common stock having an aggregate offering price of up to $215,585,139 million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions to SVB Securities and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under the Sales Agreement as a source of financing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently plan to use the net proceeds we receive from this offering to fund activities related to the commercialization of ARIKAYCE, potential commercial launch of brensocatib, if approved, and further research and development of ARIKAYCE, brensocatib, TPIP, our early-stage research efforts or any of our product candidates, and for other general corporate purposes, including business expansion activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This expected use of our net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amount and timing of our actual expenditures may vary significantly depending on numerous factors, the most significant of which are expenses related to our commercialization efforts for ARIKAYCE and brensocatib, if approved, expenses related to future ARIKAYCE, brensocatib and TPIP clinical trials, as well as any strategic transactions that we may enter into with third parties, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds we receive from this offering. We have no current understandings, agreements or commitments for any material acquisitions or licenses of any compounds, product candidates, technology or businesses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pending our use of the net proceeds we receive from this offering, we intend to invest such net proceeds in a variety of capital preservation investments, including short-term, investment grade, interest bearing instruments and U.S. government securities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 38-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_306-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pDOC"><!--Anchor--></a>DESCRIPTION OF COMMON STOCK</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the material terms of our common stock, which is based upon, and is qualified in its entirety by reference to, our Articles of Incorporation, as amended (the &#8220;Articles of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and applicable provisions of the Virginia Stock Corporation Act (&#8220;VSCA&#8221;). This summary may not contain all the information that is important to you; you can obtain additional information regarding our Articles of Incorporation and Bylaws by referring to such documents, copies of which are included as exhibits to the registration statement of which this prospectus forms a part.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">General</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our Articles of Incorporation, we have authority to issue 500,000,000 shares of common stock, par&#160;value $0.01 per share. As of March&#160;14, 2023, there were 136,428,466 shares of common stock issued and outstanding. All shares of common stock will, when issued pursuant to this prospectus, be duly authorized, fully paid and nonassessable.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Dividend Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the rights of the holders of any of our preferred stock then outstanding, the holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this prospectus, we have not declared or paid any dividends on our shares of common stock, and there were no shares of preferred stock outstanding, although our board of directors is authorized to issue preferred stock with rights senior to those of the common stock without any further vote or action by the holders of our common stock.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Rights Upon Liquidation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of common stock will receive distributions pro rata out of assets that we can legally use to pay distributions, subject to the rights of the holders of any of our preferred stock then outstanding.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock are entitled to one vote per share and will have the exclusive power to vote on all matters presented to our shareholders, including the election of directors, except as otherwise provided by the VSCA and subject to the rights of the holders of any of our preferred stock then outstanding. An election of directors by our shareholders will be determined by a plurality of the votes cast by the shareholders entitled to vote on the election, although we have a director resignation policy applicable to director nominees in uncontested elections. Our Articles of Incorporation do not provide for cumulative voting. In accordance with our Articles of Incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year at our annual meeting of shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to certain exceptions set forth in the VSCA, matters other than the election of directors generally will be approved if the votes cast by our shareholders favoring the action exceed the votes cast opposing the action. Subject to the rights of the holders of any of our preferred stock then outstanding, however, the affirmative vote of at least 75% of the voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single group, will be required to take the following actions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">remove a director, which may only be done for cause; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">alter, amend, repeal, or adopt any provision inconsistent with, the provisions of (1) our Articles of Incorporation that provide for a classified board, director removal only for cause, filling of newly created or vacant directorships, or bylaw amendments or (2) our Bylaws.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Other Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock will have no preference, appraisal or exchange rights, except for any appraisal rights provided by the VSCA. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 39-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_306-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Potential Anti-Takeover Effects of Certain Provisions of Virginia Law and Our Organizational Documents </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain provisions of the VSCA, our Articles of Incorporation and our Bylaws could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The requirement that shareholders provide advance notice when nominating director candidates to serve on our board of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inability of shareholders to convene a shareholders&#8217; meeting without the chair of the board, the president or a majority of the board of directors first calling the meeting.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, LLC. Its address is 1717 Arch Street, Suite 1300, Philadelphia, PA 19103.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;INSM.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 40-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_306-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pDIL"><!--Anchor--></a>DILUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.5pt;">Our historical net tangible book deficit as of March&#160;31, 2023 was $(248.3) million, or $(1.82) per share of our common stock, based upon 136,429,216 shares outstanding on March&#160;31, 2023. Net tangible book value (deficit) per&#160;share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of March&#160;31, 2023. After giving effect to the assumed sale by us of an aggregate of 11,187,604 shares of our common stock at an assumed offering price of $19.27 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on May 15, 2023, for aggregate gross proceeds of $215.6 million, and after deducting commissions and offering expenses payable by us, our as-adjusted net tangible book deficit would have been $(39.8) million, or $(0.27) per share of common stock. This represents an immediate increase in net tangible book value of $1.55 per share to our existing shareholders and an immediate dilution in net tangible book value of $19.54 per share to investors purchasing shares of our common stock at the assumed offering price of $19.27 per share in this offering. The following table illustrates this calculation on a per share basis:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed offering price per share<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$19.27</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net tangible book deficit per share as of March&#160;31, 2023<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(1.82)</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Increase in net tangible book value per share attributable to investors purchasing shares of our common stock in this offering<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000;">$</font><font style="border-bottom: 1pt solid #000000;">1.55</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As-adjusted net tangible book deficit per share after this offering<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000;">$</font><font style="border-bottom: 1pt solid #000000;">(0.27)</font></div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dilution per share to investors purchasing shares of our common stock in this offering<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000;">$</font><font style="border-bottom: 3pt double #000000;">19.54</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The foregoing table and calculations are based on upon 136,429,216 shares of our common stock outstanding as of March&#160;31, 2023, and exclude:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">19,155,595 shares of our common stock issuable upon the exercise of stock options outstanding as of March&#160;31, 2023 at a weighted average exercise price of $21.74 per share&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">2,057,694 shares of our common stock issuable pursuant to unvested RSUs outstanding as of March&#160;31, 2023 at a weighted average grant price of $21.38; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">671,112 shares of our common stock issuable pursuant to unvested PSUs outstanding as of March&#160;31, 2023 at a weighted average grant price of $26.43;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">10,745,789 shares of our common stock reserved for issuance under the Plan, which reflects shares reserved under the Plan as of March&#160;31, 2023, as well as an additional 10,500,000 shares of common stock reserved after March&#160;31, 2023 in connection with the adoption of the Plan (plus any shares subject to outstanding awards as of March&#160;31, 2023 under our 2017 Incentive Plan, 2015 Incentive Plan and 2013 Incentive Plan that subsequently are cancelled, terminated unearned, expired, forfeited, lapsed for any reason or are settled in cash without the delivery of shares)&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,014,939 shares of our common stock reserved for issuance under our Employee Stock Purchase Plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,746,140 shares of our common stock reserved for issuance upon conversion of our 2025 Notes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">17,692,290 shares of our common stock reserved for issuance upon conversion of our 2028 Notes; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">9,456,112 shares of our common stock reserved for issuance as acquisition consideration in connection with our acquisitions of Motus Biosciences, Inc., AlgaeneX, Inc. and Vertuis Bio, Inc.; and </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11pt;">The information discussed above is illustrative only and the shares subject to our Sales Agreement with SVB Securities are being sold from time to time at various prices. Investors purchasing shares of our common stock in this offering will experience further dilution upon, among other things, the future exercise of stock options, vesting of RSUs and PSUs, conversion of some or all of our 2025 Notes and 2028 Notes to the extent we deliver shares upon conversion of the notes, and issuance of shares in connection with our acquisitions. Furthermore, we may choose to raise additional capital through the sale of additional securities due to market conditions or strategic considerations even if we believe we have sufficient funds on hand for our current or future operating plans. To the extent that we raise additional capital in this manner, the issuance of such securities would likely result in further dilution to investors purchasing shares of our common stock in this offering.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 41-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_307-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We previously entered into the Sales Agreement with SVB Securities relating to the issuance and sale of shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreement, pursuant to this prospectus, we may issue and sell up to $215,585,139 of shares of our common stock from time to time through SVB Securities acting as agent (the &#8220;Agent&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agent may sell our common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act, including sales made directly on the Nasdaq Global Select Market, on any other existing trading market for our common stock, or to or through a market maker. We may instruct the Agent not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or the Agent may suspend the offering of common stock upon notice and subject to other conditions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will pay the Agent commissions, in cash, for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse the Agent for certain specified expenses, including the fees and disbursements of their legal counsel, in an amount not to exceed $50,000, as well as certain ongoing fees of their legal counsel, plus an additional amount not to exceed $10,000 for their Financial Industry Regulatory Agency, Inc. (&#8220;FINRA&#8221;) counsel fee. In accordance with FINRA Rule 5110, these reimbursed fees and expenses are deemed sales compensation to the Agent in connection with this offering. We estimate that the total expenses for the offering, excluding discounts and commissions payable to the Agent under the terms of the Sales Agreement, will be approximately $700,000.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Agent will provide written confirmation to us no later than the opening of the trading day on the Nasdaq Global Select Market after each trading day on which common stock is sold through it as sales agent under the Sales Agreement. Each confirmation will include the number or amount of shares sold through it as sales agent on that day, the volume-weighted average price of the shares sold and the net proceeds to us from such sales.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Settlement for sales of common stock will occur on the second trading day following the date on which any sales are made, or on some other date that is agreed upon by us and the Agent in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and the Agent may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Agent will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common stock under the terms and subject to the conditions set forth in the Sales Agreement. In connection with the sale of the common stock on our behalf, the Agent will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Agent against certain civil liabilities, including liabilities under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The offering of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. We and the Agent (with respect to itself) may terminate the Sales Agreement at any time upon ten days&#8217; prior notice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Agent and/or its respective affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, the Agent will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus in electronic format may be made available on a website maintained by the Agent and the Agent may distribute this prospectus electronically.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 42-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_307-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pLM"><!--Anchor--></a>LEGAL MATTERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain legal matters in connection with this offering will be passed upon for us by Covington &amp; Burling LLP, Washington, D.C. The validity of the common stock being offered hereby will be passed upon for us by Hunton Andrews Kurth LLP, Richmond, Virginia. Ropes &amp; Gray LLP, Boston, Massachusetts, is counsel to SVB Securities in connection with this offering.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="pEXP"><!--Anchor--></a>EXPERTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, and the effectiveness of our internal control over financial reporting as of December&#160;31, 2022, as set forth in their reports, which are incorporated by reference in this prospectus. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s reports, given on their authority as experts in accounting and auditing. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 43-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_307-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="pIOC"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring to those publicly available documents. The information that we incorporate by reference is considered to be part of this prospectus. We incorporate by reference the documents listed below (File No. 000-30739) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of this prospectus and the date this offering is terminated: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450623000009/insm-20221231.htm">February&#160;23, 2023</a>;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2022 from our definitive proxy statement on Schedule 14A, as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123015322/ny20006571x1_def14a.htm">March&#160;31, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Quarterly Report on Form 10-Q for the quarter ended on March&#160;31, 2023, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450623000012/insm-20230331.htm">May&#160;4, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Current Report on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123024132/brhc20052827_8k.htm">May&#160;11, 2023</a>; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Description of our common stock contained in our registration statement on Form 8-A, dated June&#160;1, 2000, as updated by the Description of Securities Registered Under Section 12 of the Exchange Act, filed as <a href="https://www.sec.gov/Archives/edgar/data/1104506/000110450621000005/insm20201231ex45.htm">Exhibit 4.7</a> to our Annual Report on Form 10-K for the year ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">December&#160;31, 2021</a>, and including any amendment or report subsequently filed for the purpose of updating such description.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may access our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statement, and other information, if any, we file with or furnish to the SEC free of charge at the SEC&#8217;s website (www.sec.gov) or our website (www.insmed.com) as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may also request a copy of our SEC filings at no cost, by telephoning or writing us at the following telephone number or address:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Insmed Incorporated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">700 US Highway 202/206<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Michael A. Smith, General Counsel<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(908) 977-9900 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 44-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009120x1_s3asr_308-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 153.5pt; text-align: center;">$215,585,139</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 31.25pt; text-align: center;"><img style="height: 99px; width: 293px;" src="logo_insmedx1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 32.5pt; text-align: center;">Common Stock</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 32.5pt; text-align: center;">PROSPECTUS</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 31.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 32.5pt; text-align: center;">SVB Securities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 24.5pt; text-align: center;">May 19, 2023</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 182.5pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 45-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009120x1_s3asr_400-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Up to 27,793 Shares</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 83px; width: 244px;" src="logo_insmed.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Common Stock</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the offer and sale from time to time by the selling shareholder named herein, or its permitted transferees (the &#8220;selling shareholder&#8221;) of up to 27,793 shares of our common stock, par value $0.01 per share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selling shareholder may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of shares of common stock. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The selling shareholder will bear all commissions and discounts, if any, attributable to its sale of shares of common stock. See &#8220;Plan of Distribution.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;INSM&#8221;. The last reported sale price of our common stock on the Nasdaq Global Select Market on May 18, 2023 was $18.82 per share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#sRF">7</a> of this prospectus and the documents incorporated by reference into this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Prospectus dated May 19, 2023</div></div></div></div>
<!--End Page 46-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_401-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Prospectus</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sATP"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sFLS">FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.89pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sFLS"><font style="padding-left: 5pt;">2</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPS">PROSPECTUS SUMMARY<font style="padding-left: 2.84pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPS"><font style="padding-left: 5pt;">5</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sTO">THE OFFERING<font style="padding-left: 2.85pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sTO"><font style="padding-left: 5pt;">6</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sRF"><font style="padding-left: 5pt;">7</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sUOP"><font style="padding-left: 5pt;">8</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sDOC">DESCRIPTION OF COMMON STOCK<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sDOC"><font style="padding-left: 5pt;">9</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sSS">SELLING SHAREHOLDER<font style="padding-left: 1.2pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sSS"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPOD">12</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sLM">14</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sEXP">14</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sIOC">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE<font style="padding-left: 4.67pt;"></font></a></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sIOC">15</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 47-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_402-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) using a shelf registration process. This prospectus provides you with a general description of the shares of common stock that may be resold by the selling shareholder. To the extent the information contained in this prospectus differs or varies from the information contained in documents previously filed with the SEC that are incorporated by reference herein, the information in this prospectus will supersede such information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In certain circumstances, we may provide a prospectus supplement that will contain specific information about the terms of a particular offering by the selling shareholder. We also may provide a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus or any prospectus supplement&#8212;the statement in the later-dated document modifies or supersedes the earlier statement.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a more detailed understanding of an investment in our common stock, you should read this prospectus, together with any applicable prospectus supplement and the information incorporated by reference herein and therein and additional information described under the heading &#8220;Incorporation of Certain Documents by Reference&#8221; in this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Company nor the selling shareholder has authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus and in any related prospectus supplement or free writing prospectus filed by us with the SEC. Accordingly, neither the Company nor the selling shareholder takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. Neither the Company nor the selling shareholder is making offers to sell or seeking offers to buy shares of our common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus, any applicable prospectus supplement, the documents incorporated by reference herein and therein and any related free writing prospectus is accurate only as of the respective dates of such documents, regardless of the time of delivery of this prospectus or any sale of the common stock offered hereby. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the context otherwise indicates, references in this prospectus to &#8220;Insmed&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated, a Virginia corporation, together with its consolidated subsidiaries. INSMED and ARIKAYCE are trademarks of Insmed Incorporated. Our logos and trademarks are the property of Insmed. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217; trademarks or trade dress in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 48-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_403-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sFLS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the other documents that are incorporated herein by reference contain forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements&#8221;, as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act are statements that are not historical facts and involve a number of risks and uncertainties. Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking&#160;statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully commercialize ARIKAYCE, our only approved product, in the United States (&#8220;U.S.&#8221;), Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner complete the study to validate a patient reported outcome tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability of us, PARI Pharma GmbH (&#8220;PARI&#8221;) or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira Nebulizer System (&#8220;Lamira&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, treprostinil palmitil inhalation powder (&#8220;TPIP&#8221;) or our other product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 49-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_403-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, or for our product candidates in the U.S., Europe, Japan or other markets, including separate regulatory approval for Lamira in each market and for each usage;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to attract and retain key personnel or to effectively manage our growth; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks that our acquired technologies, products and product candidates are not commercially successful;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adapt to our highly competitive and changing environment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that we are unable to maintain our significant customers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that government healthcare reform materially increases our costs and damages our financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impact of the COVID-19 pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB, and failure to comply with our obligations under such agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our limited experience operating internationally;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our history of operating losses, and the possibility that we never achieve or maintain profitability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">goodwill impairment charges affecting our results of operations and financial condition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 50-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_403-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not actually achieve the results, plans, intentions or expectations indicated by our forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These risks and uncertainties include, but are not limited to, those described above, in the &#8220;Risk Factors&#8221; section of this prospectus, in the &#8220;Risk Factors&#8221; section of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus and any applicable prospectus supplement, as updated by our subsequent filings under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation, except as specifically required by law, and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in such forward-looking statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this prospectus, any applicable prospectus supplement, and the documents incorporated by reference herein and therein with the understanding that our actual future results may be materially different from those expressed in forward-looking statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 51-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009120x1_s3asr_404-sum_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sPS"><!--Anchor--></a>PROSPECTUS SUMMARY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary highlights selected information included or incorporated by reference in this prospectus and does not contain all of the information that may be important to you. You should carefully review this entire prospectus and any applicable prospectus supplement, including the risk factors and financial statements and related notes thereto included or incorporated by reference herein and therein, before making a decision to purchase our common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the U.S. as ARIKAYCE&#174; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the U.S. in September 2018 for the treatment of <font style="font-style: italic;">Mycobacterium avium </font>complex (&#8220;MAC&#8221;) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission approved ARIKAYCE for the treatment of nontuberculous mycobacterial (&#8220;NTM&#8221;) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (&#8220;CF&#8221;). In March 2021, Japan&#8217;s Ministry of Health, Labour and Welfare approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our clinical-stage pipeline includes brensocatib, TPIP and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which we are developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps. TPIP is an inhaled formulation of the treprostinil prodrug trespostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. Our early-stage research programs encompass a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated in the Commonwealth of Virginia on November&#160;29, 1999. On December&#160;1, 2010, we completed a business combination with Transave, Inc., a privately held New Jersey-based company focused on the development of differentiated and innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. Our principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807, and our telephone number is (908) 977-9900. Our website address is www.insmed.com. The information on our website is not incorporated by reference into this prospectus and should not be considered to be part of this document.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 52-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20009120x1_s3asr_404-sum_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sTO"><!--Anchor--></a>THE OFFERING</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 228pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common stock offered by the selling shareholder<font style="font-weight: normal; padding-left: 5.5pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 252pt; text-align: left;">Up to 27,793 shares of our common stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 228pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Manner of offering<font style="font-weight: normal; padding-left: 4.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 252pt; text-align: left;">The selling shareholder will determine when and how it will sell the shares of common stock offered in this prospectus, as described in the &#8220;Plan of Distribution&#8221; on page <a href="#sPOD">12</a> of this prospectus. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 228pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="font-weight: normal; padding-left: 1.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 252pt; text-align: left;">We will not receive any proceeds from the sale of the common stock by the selling shareholder in this offering. See &#8220;Use of Proceeds&#8221; on page <a href="#sUOP">8</a> of this prospectus for additional information. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 228pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors<font style="font-weight: normal; padding-left: 5.3pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 252pt; text-align: left;">An investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#sRF">7</a> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider before deciding to invest in our common stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 228pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Nasdaq Global Select Market listing<font style="font-weight: normal; padding-left: 1.77pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 252pt; text-align: left;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;INSM&#8221;. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 53-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_405-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sRF"><!--Anchor--></a>RISK FACTORS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An investment in our common stock involves significant risks. Before making an investment in our common stock, you should carefully read all of the information contained in this prospectus, in any applicable prospectus supplement and in the documents incorporated by reference herein and therein. For a discussion of risks that you should carefully consider before deciding to purchase any of our common stock, please review the risk factors set forth in the &#8220;Risk Factors&#8221; section of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus and any applicable prospectus supplement, as updated by our subsequent filings under the Exchange Act. Any of these risks, as well as additional risks not currently known to us or that we currently deem immaterial, may adversely affect our business, financial condition, results of operations, and prospects, resulting in a decline in the trading price of our common stock and loss of all or part of your investment.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 54-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_406-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sUOP"><!--Anchor--></a>USE OF PROCEEDS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus and any accompanying prospectus supplement. All proceeds from the sale of the shares of common stock will be for the account of the selling shareholder or its permitted transferees.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 55-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_407-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sDOC"><!--Anchor--></a>DESCRIPTION OF COMMON STOCK</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the material terms of our common stock, which is based upon, and is qualified in its entirety by reference to, our Articles of Incorporation, as amended (the &#8220;Articles of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and applicable provisions of the Virginia Stock Corporation Act (&#8220;VSCA&#8221;). This summary may not contain all the information that is important to you; you can obtain additional information regarding our Articles of Incorporation and Bylaws by referring to such documents, copies of which are included as exhibits to the registration statement of which this prospectus forms a part.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">General</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our Articles of Incorporation, we have authority to issue 500,000,000 shares of common stock, par&#160;value $0.01 per share. As of March&#160;14, 2023, there were 136,428,466 shares of common stock issued and outstanding. All shares of common stock will, when issued pursuant to this prospectus, be duly authorized, fully paid and nonassessable.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Dividend Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the rights of the holders of any of our preferred stock then outstanding, the holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this prospectus, we have not declared or paid any dividends on our shares of common stock, and there were no shares of preferred stock outstanding, although our board of directors is authorized to issue preferred stock with rights senior to those of the common stock without any further vote or action by the holders of our common stock.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Rights Upon Liquidation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of common stock will receive distributions pro rata out of assets that we can legally use to pay distributions, subject to the rights of the holders of any of our preferred stock then outstanding.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock are entitled to one vote per share and will have the exclusive power to vote on all matters presented to our shareholders, including the election of directors, except as otherwise provided by the VSCA and subject to the rights of the holders of any of our preferred stock then outstanding. An election of directors by our shareholders will be determined by a plurality of the votes cast by the shareholders entitled to vote on the election, although we have a director resignation policy applicable to director nominees in uncontested elections. Our Articles of Incorporation do not provide for cumulative voting. In accordance with our Articles of Incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year at our annual meeting of shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to certain exceptions set forth in the VSCA, matters other than the election of directors generally will be approved if the votes cast by our shareholders favoring the action exceed the votes cast opposing the action. Subject to the rights of the holders of any of our preferred stock then outstanding, however, the affirmative vote of at least 75% of the voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single group, will be required to take the following actions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">remove a director, which may only be done for cause; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">alter, amend, repeal, or adopt any provision inconsistent with, the provisions of (1) our Articles of Incorporation that provide for a classified board, director removal only for cause, filling of newly created or vacant directorships, or bylaw amendments or (2) our Bylaws.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Other Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock will have no preference, appraisal or exchange rights, except for any appraisal rights provided by the VSCA. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 56-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_407-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Potential Anti-Takeover Effects of Certain Provisions of Virginia Law and Our Organizational Documents </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain provisions of the VSCA, our Articles of Incorporation and our Bylaws could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The requirement that shareholders provide advance notice when nominating director candidates to serve on our board of directors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inability of shareholders to convene a shareholders&#8217; meeting without the chair of the board, the president or a majority of the board of directors first calling the meeting.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, LLC. Its address is 1717 Arch Street, Suite 1300, Philadelphia, PA 19103.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;INSM.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 57-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_407-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sSS"><!--Anchor--></a>SELLING SHAREHOLDER</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the resale by the selling shareholder from time to time of up to 27,793 shares of common stock. We will not receive any proceeds from the sale of shares of common stock by the selling shareholder pursuant to this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selling shareholder may from time to time offer and sell any or all of the common stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term &#8220;selling shareholder&#8221; includes the shareholder listed in the table below and its permitted transferees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April 2022, the Company entered into a letter agreement with the selling shareholder, setting forth the high-level terms of a potential partnership to advance the Company&#8217;s duchenne muscular dystrophy (&#8220;DMD&#8221;) research and development program. On May&#160;6, 2023, the Company and CureDuchenne Ventures, LLC entered into a stock purchase agreement pursuant to which the Company appointed the selling shareholder as the Company&#8217;s &#8220;foundation of choice&#8221; for the Company&#8217;s DMD research and development program, and the Company issued and sold to the selling shareholder 27,793 shares of our common stock. The Company agreed to prepare and file with the SEC a registration statement with respect to resales of the 27,793 shares of common stock purchased by the selling shareholder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as set forth in the footnotes below, the following table sets forth certain information as of May 18, 2023 regarding the beneficial ownership of our common stock by the selling shareholder and the shares of common stock being offered by the selling shareholder. The applicable percentage ownership of common stock is based on approximately 136,429,216 shares of our common stock outstanding as of March&#160;31, 2023. Information with respect to shares of common stock owned beneficially after the offering assumes the sale of all of the shares of common stock registered hereby and assumes no further acquisitions or dispositions of shares by the selling shareholder. The selling shareholder may offer and sell some, all or none of its shares of common stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. A person is a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of the security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of the security, or has the right to acquire such powers within 60 days. The selling shareholder has sole voting and investment power with respect to its beneficially owned common stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Please see &#8220;Plan of Distribution&#8221; in this prospectus for further information regarding the selling shareholder&#8217;s method of distributing these shares.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 57.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Common Stock</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Selling Shareholder</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned Prior to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Registered for Sale <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hereby</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Offering</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Offering</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CureDuchenne Ventures, LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.92pt;"></font></div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;">27,793</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.08%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.19pt; text-align: left;">27,793</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.34%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.54pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.58pt; text-align: left;">&#8212;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Debra Miller, the President and Chief Executive Officer of Cure Duchenne Ventures, LLC, holds sole voting and dispositive power over the shares held by Cure Duchenne Ventures, LLC.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 58-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_408-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are registering the resale by the selling shareholder of up to 27,793 shares of common stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are required to pay all fees and expenses incident to the registration of the securities to be offered and sold pursuant to this prospectus. The selling shareholder will bear all commissions and discounts, if any, attributable to their sale of shares of our common stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will not receive any of the proceeds from the sale of common stock by the selling shareholder. The aggregate proceeds to the selling shareholder will be the purchase price of the common stock less any discounts and commissions borne by the selling shareholder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The shares of common stock beneficially owned by the selling shareholder covered by this prospectus may be offered and sold from time to time by the selling shareholder. The term &#8220;selling shareholder&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from the selling shareholder as a gift, pledge, partnership distribution or other transfer. The selling shareholder will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling shareholder may sell its shares of common stock by one or more of, or a combination of, the following methods:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ordinary brokerage transactions and transactions in which the broker solicits purchasers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">over-the-counter distributions in accordance with the rules of Nasdaq;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters, agents or broker-dealers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privately negotiated transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">options transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through a combination of any of the above methods of sale; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted pursuant to applicable law.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, any securities that qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant to this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the common stock or otherwise, the selling shareholder may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of common stock in the course of hedging the positions they assume with the selling shareholder. The selling shareholder may also sell shares of common stock short and redeliver the shares to close out such short positions. The selling shareholder may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling shareholder may also pledge shares of common stock to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 59-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_408-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selling shareholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If an applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell shares of common stock covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by or borrowed from the selling shareholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from the selling shareholder in settlement of those derivatives to close out any related open borrowings of stock. If treated as so under applicable securities laws, the third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, the selling shareholder may otherwise loan or pledge shares of common stock to a financial institution or other third party that in turn may sell the shares short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In effecting sales, broker-dealers or agents engaged by the selling shareholder may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling shareholder in amounts to be negotiated immediately prior to the sale.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In offering the shares of common stock covered by this prospectus, the selling shareholder and any broker-dealers who execute sales for them may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the selling shareholder, and the compensation of any broker-dealer who executes sales for them, may be deemed to be underwriting discounts and commissions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to comply with the securities laws of certain states, if applicable, the common stock must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the shares of common stock may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will make copies of this prospectus available to the selling shareholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholder may indemnify any broker-dealer that participates in transactions involving the sale of the common stock against certain liabilities, including liabilities arising under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the time a particular offer of shares of common stock is made, if required, a prospectus supplement will be distributed that will set forth the number of shares being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 60-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_408-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sLM"><!--Anchor--></a>LEGAL MATTERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The validity of the common stock being offered hereby will be passed upon for us by Hunton Andrews Kurth LLP, Richmond, Virginia. If legal matters are passed upon by counsel for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="sEXP"><!--Anchor--></a>EXPERTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, and the effectiveness of our internal control over financial reporting as of December&#160;31, 2022, as set forth in their reports, which are incorporated by reference in this prospectus. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s reports, given on their authority as experts in accounting and auditing. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 61-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_408-plan_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sIOC"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring to those publicly available documents. The information that we incorporate by reference is considered to be part of this prospectus. We incorporate by reference the documents listed below (File No. 000-30739) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of this prospectus and the date this offering is terminated: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450623000009/insm-20221231.htm">February&#160;23, 2023</a>;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2022 from our definitive proxy statement on Schedule 14A, as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123015322/ny20006571x1_def14a.htm">March&#160;31, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Quarterly Report on Form 10-Q for the quarter ended on March&#160;31, 2023, as filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450623000012/insm-20230331.htm">May&#160;4, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Current Report on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000114036123024132/brhc20052827_8k.htm">May 11, 2023</a>; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Description of our common stock contained in our registration statement on Form 8-A, dated June&#160;1, 2000, as updated by the Description of Securities Registered Under Section 12 of the Exchange Act, filed as <a href="https://www.sec.gov/Archives/edgar/data/1104506/000110450621000005/insm20201231ex45.htm">Exhibit 4.7</a> to our Annual Report on Form 10-K for the year ended<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm"> December&#160;31, 2021</a>, and including any amendment or report subsequently filed for the purpose of updating such description.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may access our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statement, and other information, if any, we file with or furnish to the SEC free of charge at the SEC&#8217;s website (www.sec.gov) or our website (www.insmed.com) as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may also request a copy of our SEC filings at no cost, by telephoning or writing us at the following telephone number or address:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Insmed Incorporated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">700 US Highway 202/206<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Bridgewater, New Jersey 08807<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Michael A. Smith, General Counsel<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(908) 977-9900</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 62-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20009120x1_s3asr_409-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 189.5pt; text-align: center;">Up to 27,793 Shares</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 31.25pt; text-align: center;"><img style="height: 99px; width: 293px;" src="logo_insmedx1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13pt; font-weight: bold; margin-top: 32.5pt; text-align: center;">Common Stock</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 12.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13pt; font-weight: bold; margin-top: 44.5pt; text-align: center;">PROSPECTUS</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 43.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 11pt; margin-top: 38.5pt; text-align: center;">May 19, 2023</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 156.5pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 63-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_410-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Expenses of Issuance and Distribution</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the costs and expenses (other than underwriting discounts and commissions), payable by us in connection with the registration of the securities being registered hereby.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Be Paid</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$56.24*</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nasdaq listing fee<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer agent fees<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing and engraving expenses<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 15pt;">**</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;">$&#8195;**</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Pursuant to Rules 456(b) and 457(r) under the Securities Act, the SEC registration fee will be paid at the time of any particular offering of securities under the registration statement, and is therefore not currently determinable, other than $56.24 of fees related to the issuance and sale of up to 27,793 shares of our common stock by a selling securityholder pursuant to the registration statement. The SEC registration fees related to the offering, issuance and sale of up to $215,585,139 of our common stock under a sales agreement with SVB Securities LLC and pursuant to the registration statement was paid previously and is being carried forward pursuant to Rule 415(a)(6) under the Securities Act.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Because an indeterminate amount of securities is covered by this registration statement, the expenses in connection with the issuance and distribution of the securities cannot currently be estimated.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The VSCA permits, and our Articles of Incorporation require, indemnification of our directors and officers in a variety of circumstances, which may include indemnification for liabilities under the Securities Act. Under the VSCA, a Virginia corporation is generally authorized to indemnify its directors and officers in civil or criminal actions if they acted in good faith and believed their conduct to be in the best interests of the corporation and, in the case of criminal actions, had no reasonable cause to believe that the conduct was unlawful, or if they engaged in conduct for which broader indemnification has been made permissible or obligatory us. The VSCA requires such indemnification, unless limited by a corporation&#8217;s articles of incorporation, when a director or officer entirely prevails in the defense of any proceeding to which he or she was a party because he or she is or was a director or officer of the corporation. The VSCA provides that a corporation may make any other or further indemnity (including indemnity with respect to a proceeding by or in the right of the corporation), and may make additional provision for advances and reimbursement of expenses, if authorized by its articles of incorporation or shareholder-adopted bylaw or resolution, except an indemnity against willful misconduct or a knowing violation of the criminal law. Our Articles of Incorporation require indemnification of directors and officers with respect to certain liabilities, expenses and other amounts imposed upon them because of having been a director or officer, except in the case of willful misconduct or a knowing violation of criminal law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The VSCA establishes a statutory limit on liability of directors and officers of a corporation for damages assessed against them in a suit brought by or in the right of the corporation or brought by or on behalf of the corporation&#8217;s shareholders and authorizes a corporation to specify a lower monetary limit on liability (including&#160;the elimination of liability for monetary damages) in the corporation&#8217;s articles of incorporation or shareholder-approved bylaws; however, the liability of a director or officer shall not be limited if such director or officer engaged in willful misconduct or a knowing violation of the criminal law or of any federal or state securities law, including, without limitation, any unlawful insider trading or manipulation of the market for any security. As permitted by the VSCA, our Articles of Incorporation provide that no director or officer shall be liable to us or our shareholders for monetary damages with respect to any transaction, occurrence or course of conduct, except for liability resulting from such person&#8217;s having engaged in willful misconduct or a knowing violation of the criminal law or any federal or state securities law.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 64-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_410-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain directors and officers have been granted contractual indemnification rights under separate indemnification agreements with us, pursuant to which they will be entitled to indemnification from us under certain circumstances. Additionally, the employment agreements we have entered into with our executive officers provide for indemnification to the fullest extent permitted by law from and against any and all claims, damages, expenses (including attorneys&#8217; fees), judgments, penalties, fines, settlements, and all other liabilities incurred or paid by the executive officer in connection with the investigation, defense, prosecution, settlement or appeal of any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative in nature, and to which the executive officer was or is a party or is threatened to be made a party by reason of the fact that he or she is or was an officer, employee or agent of the Company, or by reason of anything done or not done by him or her in any such capacity or capacities, provided that such executive officer acted in good faith, in a manner that was not grossly negligent or that constituted willful misconduct and in a manner he or she reasonably believed to be in or not opposed to the Company&#8217;s best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. We also carry insurance on behalf of directors, officers, employees or agents that may cover liabilities under the Securities Act.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 65-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 66-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_411-exind_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits</div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">EXHIBIT INDEX</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 7.69%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 91.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">**1.1</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Underwriting Agreement.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="https://www.sec.gov/Archives/edgar/data/1104506/000114036121006108/nt10020763x2_ex10-1.htm">1.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sales Agreement, dated as of February&#160;25, 2021, by and between Insmed Incorporated and SVB Leerink LLC (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on February&#160;25, 2021).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="https://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm">3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit 3.1 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed on March&#160;18, 2013).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="https://www.sec.gov/Archives/edgar/data/1104506/000114036123024132/brhc20052827_ex3-1.htm">3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit 3.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on May 11, 2023).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="https://www.sec.gov/Archives/edgar/data/1104506/000091664100000328/0000916641-00-000328.txt">4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Specimen stock certificate representing common stock, $0.01 par value per share, of Insmed Incorporated (incorporated by reference from Exhibit 4.2 to Insmed Incorporated's Registration Statement on Form S-4/A (Registration No. 333-30098) filed on March&#160;24, 2000).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="https://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d1.htm">4.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Indenture, dated as of January&#160;26, 2018, by and between Insmed Incorporated and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association) (incorporated by reference from Exhibit 4.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on January&#160;26, 2018).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">**4.3</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Debt Security.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex5-1.htm">*5.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Hunton Andrews Kurth LLP, counsel to the registrant.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex5-2.htm">*5.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Covington &amp; Burling LLP, counsel to the registrant.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex23-1.htm">*23.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex5-1.htm">*23.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Hunton Andrews Kurth LLP (included in Exhibit 5.1).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex5-2.htm">*23.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Covington &amp; Burling LLP (included in Exhibit 5.2).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tPOA">*24.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on signature page hereto).</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex25-1.htm">*25.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Statement of Eligibility of Computershare Trust Company, N.A. on Form T-1.</div></td></tr><tr><td style="width: 7.69%; text-align: right; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="ny20009120x1_ex107.htm">*107</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table.</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Filed herewith.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be subsequently filed by amendment or as an exhibit to a document to be incorporated or deemed to be incorporated by reference to this registration statement, including a Current Report on Form 8-K.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any prospectus required by Section 10(a)(3) of the Securities Act;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 66-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 67-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_411-exind_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 60pt; text-align: left;">provided<font style="font-style: normal;">, </font>however<font style="font-style: normal;">, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii)&#160;of this section do not apply if </font><font style="font-style: normal;">the information required to be included in a post-effective amendment by those paragraphs is </font><font style="font-style: normal;">contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or </font><font style="font-style: normal;">Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, </font><font style="font-style: normal;">or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration </font><font style="font-style: normal;">statement.</font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act to any purchaser:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof; <font style="font-style: italic;">provided, however</font>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 67-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 68-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_411-exind_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: left;">the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 68-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 69-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_412-sign_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SIGNATURES</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bridgewater, State of New Jersey, on May 19, 2023.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">INSMED INCORPORATED </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ William H. Lewis</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">William H. Lewis <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">President and Chief Executive Officer, </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">Chair of the Board of Directors</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 69-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 70-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20009120x1_s3asr_412-sign_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>POWER OF ATTORNEY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of William H. Lewis and Michael A. Smith his or her true and lawful attorney with power of substitution and resubstitution to sign in his or her name, place and stead in any and all such capacities the Registration Statement and any and all amendments and supplements thereto (including post-effective amendments) and documents in connection therewith, and to file the same with the SEC, said attorney to have full power and authority to do and perform, in the name of and on behalf of each of said officers and directors of the Registrant who shall have executed such a power of attorney, every act whatsoever which such attorney may deem necessary or desirable to be done in connection therewith, as fully and to all intents and purposes as such officer or director of the Registrant might or could do in person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 25.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 43.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 25.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ William H. Lewis</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chair of the Board of Directors<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(<font style="font-style: italic;">Principal Executive Officer</font>)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William H. Lewis</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sara Bonstein</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(<font style="font-style: italic;">Principal Financial Officer, Principal </font><font style="font-style: italic;">Accounting Officer</font>)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sara Bonstein</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alfred F. Altomari</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Elizabeth McKee Anderson</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David R. Brennan</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clarissa Desjardins, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leo Lee</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David W.J. McGirr</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Carol A. Schafer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 25.64%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Melvin Sharoky, M.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">*By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Michael A. Smith</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2023</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael A. Smith<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">Attorney-in-Fact</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-7<br></div></div></div>
<!--End Page 70-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ny20009120x1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 5.1</font><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9ec76e2ca0c1409a984fb2a7006f41f2" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 80%; vertical-align: top; font-size: 6pt;"><img src="ny20009120x1_ex5-1image01.jpg"></td>
          <td style="width: 20%; vertical-align: top; font-size: 6pt;">
            <div style="font-family: 'Times New Roman',Times,serif;">HUNTON ANDREWS KURTH LLP</div>
            <div style="font-family: 'Times New Roman',Times,serif;">FILE NO: 058036.0000021 </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>May 19, 2023</div>
    <div><br>
    </div>
    <div>Insmed Incorporated</div>
    <div>700 US Highway 202/206</div>
    <div>Bridgewater, New Jersey 08807</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Insmed Incorporated</div>
    <div style="text-align: center; font-weight: bold;">Registration Statement on Form S-3</div>
    <div><br>
    </div>
    <div>Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We have acted as Virginia counsel to Insmed Incorporated, a Virginia corporation (the &#8220;Company&#8221;), in connection with the preparation and
      filing by the Company of a Registration Statement on Form S-3 (the &#8220;Registration Statement&#8221;), with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on the date hereof pursuant to the Securities Act of 1933, as amended (the &#8220;Securities
      Act&#8221;).&#160; The Registration Statement contains three prospectuses (the &#8220;Prospectuses&#8221; and each a &#8220;Prospectus&#8221;) relating to the registration of: (A) an indeterminate amount of (i) the Company&#8217;s debt securities, which may be either senior debt securities
      or subordinated debt securities (&#8220;Debt Securities&#8221;), and (ii) shares (the &#8220;Shelf Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (&#8220;Common Stock&#8221;); (B) the issuance and sale of up to $215,585,139 of Common Stock (the &#8220;ATM Shares&#8221;);
      and (C) the resale of 27,793 shares of Common Stock (the &#8220;Selling Shareholder Shares&#8221; and, together with the Debt Securities, the Shelf Shares and the ATM Shares, the &#8220;Securities&#8221;) by CureDuchenne Ventures, LLC (the &#8220;Selling Stockholder&#8221;).&#160; The Debt
      Securities will be issued pursuant to one or more supplemental indentures to the indenture filed as Exhibit 4.2 to the Registration Statement (such indenture, together with the applicable supplemental indenture, the &#8220;Indenture&#8221;).&#160; The ATM Shares will
      be issued pursuant to a sales agreement, dated as of February 25, 2021, with SVB Leerink LLC (now known as SVB Securities LLC) (the &#8220;Sales Agreement&#8221;).&#160; The Selling Shareholder Shares were issued by the Company to the Selling Shareholder pursuant to
      a stock purchase agreement, dated as of May 6, 2023, between the Selling Shareholder and the Company (the &#8220;Stock Purchase Agreement&#8221;). The Securities will be offered on a continuous or delayed basis pursuant to Rule 415 of the Securities Act, from
      time to time as set forth in the Registration Statement, the Prospectuses contained therein and any amendments or supplements thereto.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">This opinion letter is being furnished in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">In connection with this opinion letter, we have examined originals or copies, certified or otherwise identified to our satisfaction, of
      such documents and records of the Company, certificates of public officials and officers of the Company and such other documents, certificates and records as we have deemed necessary to render the opinions set forth herein, including, among other
      things, (i) the Company&#8217;s Articles of Incorporation, as amended through the date hereof, (ii) the Company&#8217;s Amended and Restated Bylaws, as amended through the date hereof, (iii) the Registration Statement and the Prospectuses, (iv) resolutions of
      the Company&#8217;s Board of Directors, (v) the Sales Agreement, (vi) the Stock Purchase Agreement and (vii) a certificate issued by the Clerk of the State Corporation Commission of the Commonwealth of Virginia on the date hereof to the effect that the
      Company is existing under the laws of the Commonwealth of Virginia and in good standing (the &#8220;Good Standing Certificate&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 8pt;">ATLANTA&#160;&#160; AUSTIN&#160;&#160; BANGKOK&#160;&#160; BEIJING&#160;&#160; BOSTON&#160;&#160; BRUSSELS&#160;&#160; CHARLOTTE&#160;&#160; DALLAS&#160;&#160; DUBAI&#160;&#160; HOUSTON</div>
    <div style="text-align: center; font-size: 8pt;">LONDON&#160;&#160; LOS ANGELES&#160;&#160; MIAMI&#160;&#160; NEW YORK&#160;&#160; RICHMOND&#160;&#160; SAN FRANCISCO&#160;&#160; TOKYO&#160;&#160; TYSONS&#160;&#160; WASHINGTON, DC</div>
    <div style="text-align: center; font-size: 8pt;">www.HuntonAK.com</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><img src="ny20009120x1_ex5-1image01.jpg">
      <div><br>
      </div>
      <div>
        <div>Insmed Incorporated</div>
        <div>May 19, 2023</div>
        <div>Page 2</div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">For purposes of the opinions expressed below, we have assumed (i) the legal capacity of all natural persons, (ii) the genuineness of all
      signatures, (iii) the authenticity of all documents submitted to us as originals, (iv) the conformity to authentic original documents of all documents submitted to us as certified, electronic or photostatic copies and (v) the due authorization,
      execution and delivery of all documents by all parties and the validity, binding effect and enforceability thereof on such parties (other than the authorization, execution and delivery of certain documents by the Company).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">As to factual matters, we have relied upon, and assumed the accuracy of, representations included in the documents submitted to us, upon
      certificates of officers of the Company and upon certificates of public officials.&#160; Except as otherwise expressly indicated, we have not undertaken any independent investigation of factual matters.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We do not purport to express an opinion on any laws other than those of the Commonwealth of Virginia.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Based upon the foregoing and such other information and documents as we have considered necessary for the purposes hereof, and subject to
      the assumptions, qualifications and limitations stated herein, we are of the opinion that:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
        Company is a corporation validly existing and in good standing under the laws of the Commonwealth of Virginia.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With
        respect to any Debt Securities, the Company has the corporate power and authority to authorize the Indenture and any officers&#8217; certificate thereto and the issuance and sale of such Debt Securities and, when the Board of Directors of the Company or
        a duly constituted and acting committee thereof (such Board of Directors or committee being hereinafter referred to as the &#8220;Board&#8221;) has taken all necessary corporate action to authorize and approve the Indenture and any officers&#8217; certificate
        thereto and the issuance and sale of such Debt Securities, the Company will have the corporate power and authority to execute and deliver the Indenture and to execute, issue and deliver the related Debt Securities.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <div><img src="ny20009120x1_ex5-1image01.jpg">
        <div><br>
        </div>
        <div>
          <div>Insmed Incorporated</div>
          <div>May 19, 2023</div>
          <div>Page 3<br>
          </div>
          <div> <br>
          </div>
        </div>
      </div>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With
        respect to the Shelf Shares, the Company has the corporate power and authority to authorize the issuance and sale of the Shelf Shares and, when (a) the Board has taken all necessary corporate action to authorize and approve the issuance of such
        Shelf Shares from the then authorized number of shares of Common Stock available and (b) such Shelf Shares have been offered and sold by the Company in accordance with the terms and conditions set forth in the Registration Statement, the related
        Prospectus and any applicable prospectus supplement and delivered either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement approved by the Board upon payment of the consideration therefor or (ii) upon the
        conversion of any Debt Security, in accordance with the terms of such Debt Security or the instrument governing such Debt Security providing for such conversion as approved by the Board, for the consideration approved by the Board, such Shelf
        Shares will be validly issued, fully paid and nonassessable.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The ATM
        Shares have been duly authorized and, when issued and delivered upon payment therefor in accordance with the terms of the Sales Agreement and the related Prospectus, the ATM Shares will be validly issued, fully paid and nonassessable.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
        Selling Shareholder Shares have been duly authorized, issued and delivered by the Company to the Selling Shareholder and are validly issued, fully paid and nonassessable.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">The opinion set forth in paragraph 1 above as to the valid existence and good standing of the Company is based solely upon our review of
      the Good Standing Certificate.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We hereby consent to the filing of this opinion letter with the Commission as an exhibit to the Registration Statement and the reference to
      our firm under the heading &#8220;Legal Matters&#8221; in the Prospectuses and the Registration Statement.&#160; In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act and the
      rules and regulations of the Commission promulgated thereunder.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">This opinion letter is rendered as of the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or
      developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein.&#160; This opinion letter is expressly limited to the matters set forth above and we render no opinion, whether by implication
      or otherwise, as to any matters beyond the matters expressly set forth herein.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z03dd8bb114074224b36993940f7b4807" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div>Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div>/s/ Hunton Andrews Kurth LLP</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>ny20009120x1_ex5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 5.2</font><br>
    </div>
  </div>
  <div><br>
    <div>
      <div>
        <div>
          <div>
            <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

                <tr>
                  <td colspan="1" style="width: 70%; vertical-align: top;">
                    <div>
                      <div><img src="ny20009120x1_ex5-2image01.jpg"></div>
                    </div>
                  </td>
                  <td colspan="1" style="width: 30%; vertical-align: top;">
                    <div>
                      <div><img src="ny20009120x1_ex5-2image02.jpg"></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div><br>
          </div>
        </div>
        <div>
          <table id="zf497a2f8b3644a5ab70960063d160cc5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 70%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>May 19, 2023</div>
                </td>
              </tr>

          </table>
          <div>
            <div style="text-align: right;"><br>
            </div>
          </div>
          Insmed Incorporated</div>
        <div>700 US Highway 202/206</div>
        <div>Bridgewater, New Jersey 08807</div>
        <div>
          <div style="text-align: right;"><br>
          </div>
          Ladies and Gentlemen:</div>
        <div> </div>
        <div style="text-align: justify; text-indent: 72pt;">We have acted as special counsel to Insmed Incorporated, a Virginia corporation (the &#8220;<font style="font-style: italic;">Company</font>&#8221;), in connection with the registration by the Company under
          the Securities Act of 1933, as amended (the &#8220;S<font style="font-style: italic;">ecurities Act</font>&#8221;), of (i) shares of the Company&#8217;s common stock, par value $0.01 per share and (ii) debt securities, which may be either senior or subordinated
          and may be issued in one or more series (&#8220;<font style="font-style: italic;">Debt Securities</font>&#8221;), pursuant to the Company&#8217;s registration statement on Form S-3 (the &#8220;<font style="font-style: italic;">Registration Statement</font>&#8221;), filed with
          the Securities and Exchange Commission (the &#8220;<font style="font-style: italic;">Commission</font>&#8221;) on the date hereof.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have
          assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">We have assumed that, at the time of the issuance, sale and delivery of each series of Debt Securities, (i) the execution, delivery and performance by the Company of any supplemental indenture to
          the indenture filed as Exhibit 4.2 to the Registration Statement (such indenture, together with the applicable supplemental indenture, the &#8220;<font style="font-style: italic;">Indenture</font>&#8221;), and all actions necessary for the issuance of the
          Debt Securities, and the form and terms thereof, will comply with all requirements and restrictions, if any, applicable to the Company, whether imposed by any agreement or instrument to which the Company is a party or by which it is bound or any
          court or other governmental or regulatory body having jurisdiction over the Company or otherwise; and (ii) the Company will have duly authorized, executed and delivered the Indenture and will have duly authorized the issuance of any such Debt
          Security, and that none of such authorizations will have been modified or rescinded, and there will not have occurred any change in law affecting the validity, legally binding character or enforceability thereof. We have also assumed that the
          Debt Securities will be offered and sold in compliance with applicable federal and state securities laws and in the manner stated in the Registration Statement and the appropriate prospectus supplement. We have assumed further that the Indenture
          will be governed by and construed in accordance with the laws of the State of New York. We have assumed that each party to the Indenture other than the Company has, or will have, duly authorized, executed and delivered the Indenture and that the
          Indenture is, or will be, the valid and binding obligation of such party, enforceable against it in accordance with its terms.</div>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">We have assumed further that the Company is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Virginia and has all requisite power,
          authority and legal right to execute, deliver and perform its obligations under the Debt Securities and the Indenture. With respect to all matters of Virginia law, we note that you are relying on an opinion of Hunton Andrews Kurth LLP, dated as
          of the date hereof, which opinion is filed as Exhibit 5.1 to the Registration Statement.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">Additionally, we have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">Based upon the foregoing, and subject to the qualifications set forth herein, we are of the opinion that, when, as and if (i) the Registration Statement and any required post-effective amendments
          thereto have all become effective under the Securities Act and all prospectus supplements required by applicable law have been delivered and filed as required by such laws; (ii) the Indenture has been duly executed and delivered on behalf of the
          Company and Wells Fargo Bank, National Association, as trustee (the &#8220;<font style="font-style: italic;">Trustee</font>&#8221;) and such Indenture has been duly qualified under the Trust Indenture Act of 1939, as amended; (iii) all necessary corporate
          action has been taken by the Company to authorize, execute and deliver any necessary supplemental indenture and to authorize the form, terms, execution and delivery of the Debt Securities; (iv) any legally required consents, approvals,
          authorizations and other orders of the Commission and any other regulatory authorities have been obtained; and (v) such Debt Securities have been duly executed by the Company and authenticated by the Trustee in accordance with the Indenture and
          have been duly issued and delivered against payment therefor in accordance with such corporate action and applicable law and as contemplated in the Registration Statement and the prospectus supplement setting forth the terms of the Debt
          Securities and the plan of distribution, then, upon the happening of such events, such Debt Securities will constitute the valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to
          bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&#8217; rights and to general equity principles.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">Our opinion above is qualified to the extent that the enforcement of any Debt Securities denominated in a currency other than United States dollars may be limited by requirements that a claim (or
          a foreign currency judgment in respect of such claim) be converted into United States dollars at a rate of exchange prevailing on a date determined pursuant to applicable law.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">We express no opinion as to (i) waivers of defenses, subrogation and related rights, rights to trial by jury, rights to object to venue, or other rights or benefits bestowed by operation of law,
          (ii) releases or waivers of unmatured claims or rights, (iii) indemnification, contribution, exculpation or arbitration provisions, or provisions for the non-survival of representations, to the extent they purport to indemnify any party against,
          or release or limit any party&#8217;s liability for, its own breach or failure to comply with statutory obligations, or to the extent such provisions are contrary to public policy, (iv) provisions for liquidated damages and penalties, penalty interest
          and interest on interest, (v) provisions purporting to supersede equitable principles, including provisions requiring amendments and waivers to be in writing and provisions making notices effective even if not actually received, (vi) restrictions
          upon transfers, pledges or assignments of a party&#8217;s rights under the Indenture, or (vii) provisions purporting to make a party&#8217;s determination conclusive.</div>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">We are members of the bars of the District of Columbia and the State of New York.&#160; We do not express any opinion herein on any laws other than the law of the State of New York.</div>
        <div>&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;">We hereby consent to the filing of this opinion as Exhibit 5.2 to the Registration Statement. We also hereby consent to the reference to our firm under the heading &#8220;Legal Matters&#8221; in the
          prospectus constituting part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z16976def36f94760ba19c6a081de5855" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 50%; vertical-align: top;"><br>
              </td>
              <td style="width: 50%; vertical-align: top;">
                <div>Very truly yours,</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;"><br>
              </td>
              <td rowspan="1" style="width: 50%; vertical-align: top;"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;"><br>
              </td>
              <td style="width: 50%; vertical-align: top;">
                <div>/s/ Covington &amp; Burling LLP</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>&#160;</div>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ny20009120x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.1</div>
    <div><br>
    </div>
    <div style="text-align: center;">Consent of Independent Registered Public Accounting Firm</div>
    <div><br>
    </div>
    <div>We consent to the reference to our firm under the caption "Experts" in this Registration Statement (Form S-3) and related Prospectuses of Insmed Incorporated
      for the registration of common stock and debt securities and to the incorporation by reference therein of our reports dated February 23, 2023, with respect to the consolidated financial statements of Insmed Incorporated, and the effectiveness of
      internal control over financial reporting of Insmed Incorporated, included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.</div>
    <div><br>
    </div>
    <div>/s/ Ernst &amp; Young LLP</div>
    <div>Iselin, New Jersey</div>
    <div>May 19, 2023
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-25.1
<SEQUENCE>5
<FILENAME>ny20009120x1_ex25-1.htm
<DESCRIPTION>EXHIBIT 25.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="text-align: right; font-weight: bold;"> Exhibit 25.1<br>
  </div>
  <div style="text-align: center; font-weight: bold;"> <br>
  </div>
  <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
  <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
  <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
  <div style="text-align: center; margin-left: 4.5pt; font-size: 18pt; font-weight: bold;">
    <div>
      <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <font style="font-size: 10pt;">FORM T-1</font></div>
  <div style="text-align: center; font-weight: bold;">STATEMENT OF ELIGIBILITY</div>
  <div style="text-align: center; font-weight: bold;">UNDER THE TRUST INDENTURE ACT OF 1939 OF A</div>
  <div style="text-align: center; font-weight: bold;">CORPORATION DESIGNATED TO ACT AS TRUSTEE</div>
  <div><br>
  </div>
  <div style="text-align: center;">CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A</div>
  <div style="text-align: center;">TRUSTEE PURSUANT TO SECTION 305(b)(2)&#160; [___]</div>
  <div style="text-align: center;">
    <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="text-align: center;"> <br>
  </div>
  <div style="text-align: center; font-weight: bold;">COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION</div>
  <div style="text-align: center;">(Exact name of trustee as specified in its charter)</div>
  <div style="text-align: center;"> <br>
  </div>
  <table id="zad46ac81253e492d89b30b6ff4c03b11" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; font-weight: bold;">National Banking Association</div>
          <div style="text-align: center;">(Jurisdiction of incorporation or organization</div>
          <div style="text-align: center;">if not a U.S. national bank)</div>
        </td>
        <td style="width: 2%; vertical-align: top;">&#160;</td>
        <td style="vertical-align: top; width: 49%;">
          <div style="text-align: center; font-weight: bold;">04-3401714</div>
          <div style="text-align: center;">(I.R.S. Employer</div>
          <div style="text-align: center;">Identification Number)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 49%; vertical-align: top;" rowspan="1">&#160;</td>
        <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
        <td style="vertical-align: top; width: 49%;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; font-weight: bold;">150 Royall Street, Canton, MA</div>
          <div style="text-align: center;">(Address of principal executive offices)</div>
        </td>
        <td style="width: 2%; vertical-align: top;">&#160;</td>
        <td style="vertical-align: top; width: 49%;">
          <div style="text-align: center; font-weight: bold;">02021</div>
          <div style="text-align: center;">(Zip Code)</div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align: top;" colspan="3" rowspan="1">
          <div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">Law Department</div>
          </div>
          <div>
            <div style="text-align: center; font-weight: bold;">Computershare Trust Company, National Association</div>
            <div style="text-align: center; font-weight: bold;">150 Royall Street, Canton, MA</div>
            <div style="text-align: center; font-weight: bold;">02021</div>
            <div style="text-align: center; font-weight: bold;">(781) 575-2000</div>
            <div style="text-align: center; font-weight: bold;">(Name, address and telephone number of agent for service)</div>
          </div>
          &#160;</td>
      </tr>

  </table>
  <div style="text-align: center; font-size: 24pt; font-weight: bold;">
    <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="text-align: center; font-size: 24pt; font-weight: bold;">INSMED INCORPORATED</div>
  <div style="text-align: center;">(Exact name of obligor as specified in its charter)</div>
  <div><br>
  </div>
  <table id="z01378954277642668cd6a59c983da775" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; font-weight: bold;">Virginia</div>
          <div style="text-align: center;">(State or other jurisdiction of</div>
          <div style="text-align: center;">incorporation or organization)</div>
        </td>
        <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; font-weight: bold;">54-1972729</div>
          <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 49%; vertical-align: top;" rowspan="1">&#160;</td>
        <td style="width: 2%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
        <td style="width: 49%; vertical-align: top;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; font-weight: bold;">700 US Highway 202/206</div>
          <div style="text-align: center; font-weight: bold;">Bridgewater, New Jersey</div>
          <div style="text-align: center;">&#160;(Address of principal executive offices)</div>
        </td>
        <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
        <td style="width: 49%; vertical-align: top; text-align: center;">
          <div>&#160;</div>
          <div style="font-weight: bold;">08807</div>
          <div>(Zip Code)</div>
        </td>
      </tr>

  </table>
  <br>
  <div style="text-align: center; font-weight: bold;">
    <hr style="height: 2px; width: 10%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="text-align: center; font-weight: bold;">Debt Securities</div>
  <div style="text-align: center;">(Title of the indenture securities)</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table id="za216792b126e448ab70649886abe3927" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 1.</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">General Information.&#160; </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Furnish the following information as to the trustee:</font></div>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <table id="z50f8cf1d3b674be39767a3b5fa63fcd0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt;"><br>
        </td>
        <td style="width: 36pt; vertical-align: top;">(a)</td>
        <td style="width: auto; vertical-align: top;">
          <div>Name and address of each examining or supervising authority to which it is subject.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z5bbfe1430d0342c8b16f2ff833bce9c2" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 36pt; margin-left: 72pt;"><br>
            </div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">Comptroller of the Currency</div>
            <div style="text-align: left;">
              <div>340 Madison Avenue, 4<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
              <div>New York, NY&#160; 10017-2613</div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <br>
  <table id="zb14b96a7327540ef98467f6249c93be6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt;"><br>
        </td>
        <td style="width: 36pt; vertical-align: top;">(b)</td>
        <td style="width: auto; vertical-align: top;">
          <div>Whether it is authorized to exercise corporate trust powers.</div>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za1d1180326de4542a7927c1a0799d52b" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 36pt; margin-left: 73.2pt;"><br>
            </div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">The trustee is authorized to exercise corporate trust powers.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
  </div>
  <table id="z37e11380fa004e4aa7885cba8b5c7801" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 2.</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Affiliations with the obligor.&#160; </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">If the obligor is an affiliate of the trustee, describe such affiliation.</font></div>
        </td>
      </tr>

  </table>
  <div style="text-indent: 72pt;"> <br>
  </div>
  <div style="text-indent: 72pt;">
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 36pt; margin-left: 73.2pt;"><br>
            </div>
          </td>
          <td style="vertical-align: top; width: auto;">None.</td>
        </tr>

    </table>
  </div>
  <div style="text-indent: 72pt;"><br>
  </div>
  <table id="zc4953806aa604a5fadcc340cd2433135" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt; vertical-align: top;"><font style="font-weight: bold;">Items 3-15</font>.</td>
        <td style="width: auto; vertical-align: top;">
          <div>No responses are included for Items 3-15 of this Form T-1 because, to the best of the Trustee&#8217;s knowledge, neither the obligor nor any guarantor is in default under any Indenture for which the Trustee acts as Trustee and the Trustee is not a
            foreign trustee as provided under Item 15.</div>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <table id="zc9a21fbd04dd48a6852fdfad1f679270" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 16.</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">List of exhibits.&#160; </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">List below all exhibits filed as a part of this statement of eligibility.</font></div>
        </td>
      </tr>

  </table>
  <div style="margin-left: 73.2pt;"> <br>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z59e14e30380f43df9e2d77b2a84748fd" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 73.2pt;">1.</div>
          </td>
          <td style="align: left; vertical-align: top; width: auto;">
            <div style="text-align: left; margin-left: 9pt; text-indent: -9pt;">A copy of the articles of association of the trustee. (See Exhibit 1 to Form T-1 filed with Registration Statement No. 333-200089).</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zf3347db4598f4d91bb82c17e6455656f" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 73.2pt;">2.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">A copy of the certificate of authority of the trustee to commence business.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z3e6fb5ac9d884d8db53173da69761002" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 73.2pt;">3.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">A copy of the Comptroller of the Currency Certification of Fiduciary Powers for Computershare Trust Company, National Association.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="ze7de4ca16d834d0c8946032c849f94e1" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 72pt;">4.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">A copy of the existing bylaws of the trustee, as now in effect.&#160; (See Exhibit 4 to Form T-1 filed with Registration Statement No. 333-200089).</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z81deabb990fd45e79be3915442a0d2b0" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 72pt;">5.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">Not applicable</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z048b9088b5c743c0ad118f923e529e8e" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; margin-left: 72pt;">6.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">The consent of the Trustee required by Section 321(b) of the Act.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4e4d3138c23949198e52a26a715daef3" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 1.2pt; margin-left: 70.8pt;">7.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">A copy of the latest report of condition of the trustee published pursuant to law or the requirements of its supervising or examining authority.</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0fbb723671b7462b8262d6295221d2fc" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 1.2pt; margin-left: 70.8pt;">8.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">Not applicable</div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9348d84ddd1c46a697a894de17277be7" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top;">
          <td style="align: right; vertical-align: top; width: 9pt;">
            <div style="text-align: left; text-indent: 1.2pt; margin-left: 70.8pt;">9.</div>
          </td>
          <td style="vertical-align: top; width: auto;">
            <div style="text-align: left;">Not applicable</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-indent: 1.2pt; margin-left: 70.8pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
  <div style="text-align: center; font-weight: bold;"> <br>
  </div>
  <div>Pursuant to the requirements of the Trust Indenture Act of 1939, the trustee, Computershare Trust Company, National Association, a national banking association, organized and existing under the laws of the United States, has duly caused this
    statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in the City of St. Paul, and State of Minnesota, on the 19<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of
    May, 2023.</div>
  <div> <br>
  </div>
  <table id="zde4021008b9d449ba1a59f021f0a945b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 50%; vertical-align: top;">&#160;</td>
        <td style="vertical-align: middle;" colspan="2">
          <div style="font-weight: bold;">COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION</div>
          <div><font style="font-weight: bold;"> </font>&#160;</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: middle;">&#160;</td>
        <td style="width: 3%; vertical-align: top;">
          <div>By:</div>
        </td>
        <td style="width: 47%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
          <div>/s/&#160; Scot Sandhoefner</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: middle;">&#160;</td>
        <td style="width: 3%; vertical-align: middle;">&#160;</td>
        <td style="width: 47%; vertical-align: middle;">
          <div>Name: Scot Sandhoefner</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: middle;" rowspan="1">&#160;</td>
        <td style="width: 3%; vertical-align: middle;" rowspan="1">&#160;</td>
        <td style="width: 47%; vertical-align: middle;" rowspan="1">&#160;Title:&#160; Vice President</td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div>
    <table id="ze8aacfbe9bb4498ebe334db5ae0314f3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">EXHIBIT 2</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>A copy of the Comptroller of the Currency Certificate of Corporate Existence for Computershare Trust Company, National Association, dated March 1, 2023.</div>
    <div> <br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%;" rowspan="2" colspan="1">
              <div>&#160;<img src="ny20009120x1_ex25-1image02.jpg" height="45" border="0" width="38"></div>
            </td>
            <td style="width: 95%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>&#160;Office of the Comptroller of the Currency<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.5%; text-align: left;" rowspan="1">
              <div style="text-align: justify;">&#160;<br>
              </div>
            </td>
            <td style="width: 47.5%; text-align: right;" rowspan="1">&#160;Washington, DC 20219</td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center;"><font style="font-weight: bold;"> CERTIFICATE OF CORPORATE EXISTENCE AND FIDUCIARY POWERS</font><br>
      </div>
      <div style="text-align: center;"> <br>
      </div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; I, <br>
              </div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">&#160;Michael J. Hsu, Acting Comptroller of the Currency, do hereby certify that:</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 1.<br>
              </div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;"> The Comptroller of the Currency, pursuant to Revised Statutes 324, et seq, as amended, and 12 USC 1, et seq, as amended, has possession, custody, and control of all records pertaining
              to the chartering, regulation, and supervision of all national banking associations. </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 2.<br>
              </div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">&#8220;Computershare Trust Company, National Association,&#8221; Canton, Massachusetts (Charter No. 23148), is a national banking association formed under the laws of the United States and is authorized thereunder to
                transact the business of banking and exercise fiduciary powers on the date of this certificate.</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; <br>
              </div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">IN TESTIMONY WHEREOF, today, March 31, 2023, I have hereunto subscribed my name and caused my seal of office to be affixed to these presents at the U.S. Department of the Treasury, in
              the City of Washington, District of Columbia.</td>
          </tr>

      </table>
    </div>
    <br>
    <div style="text-align: justify; text-indent: 0.2pt; margin-right: 198.5pt; margin-left: 43.95pt;"> <br>
    </div>
    <div style="text-align: center; text-indent: 0.2pt; margin-right: 198.5pt; margin-left: 43.95pt;"><img src="ny20009120x1_ex25-1image01.jpg" height="256" border="0" width="291"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table id="z1cf782a1a4dd4dc49cd0f254f7681b68" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">EXHIBIT 3</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>A copy of the Comptroller of the Currency Certification of Fiduciary Powers for Computershare Trust Company, National Association, dated March 1, 2023.</div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%;" rowspan="2" colspan="1">
              <div>&#160;<img src="ny20009120x1_ex25-1image02.jpg" height="45" border="0" width="38"></div>
            </td>
            <td style="width: 95%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>&#160;Office of the Comptroller of the Currency<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 47.5%; text-align: left;" rowspan="1">
              <div style="text-align: justify;">&#160;<br>
              </div>
            </td>
            <td style="width: 47.5%; text-align: right;" rowspan="1">&#160;Washington. DC 20219</td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">CERTIFICATE OF CORPORATE EXISTENCE AND FIDUCIARY POWERS</div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd2708665cadc4c94874579618d4faab4" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; I, <br>
              </div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">&#160;Michael J. Hsu, Acting Comptroller of the Currency, do hereby certify that:</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2fbf0831331940b08a4a8185e902106c" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: left;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; 1.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">The Comptroller of the Currency, pursuant to Revised Statutes 324, et seq, as amended, and 12 USC 1, et seq, as amended, has possession, custody, and control of all records pertaining to the chartering,
                regulation, and supervision of all national banking associations.</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z722314af8dee4cdcbbc9bef767abfe33" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="width: 27pt;">&#160;</td>
            <td style="vertical-align: top; width: 27pt;">
              <div style="text-align: left;">&#160; &#160; &#160;&#160; 2.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">&#8220;Computershare Trust Company, National Association,&#8221; Canton, Massachusetts (Charter No. 23148), is a national banking association formed under the laws of the United States and is authorized thereunder to
                transact the business of banking and exercise fiduciary powers on the date of this certificate.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2fd07765e28d46ad816e368cafb0f041" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 54pt;"><br>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left;">&#160;IN TESTIMONY WHEREOF, today, March 31, 2023, I have hereunto subscribed my name and caused my seal of office to be affixed to these presents at the U.S. Department of the Treasury, in the City of Washington,
                District of Columbia.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; text-indent: 0.2pt; margin-right: 198.5pt; margin-left: 43.95pt;"><img src="ny20009120x1_ex25-1image01.jpg" height="256" border="0" width="291"> </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table id="z64b7955755de4cb49f8b0b2aa5a372b3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXHIBIT 6</div>
          </td>
        </tr>

    </table>
    <div>
      <div><br>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CONSENT OF THE TRUSTEE</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Pursuant to the requirements of Section 321 (b) of the Trust Indenture Act of 1939, and in connection with the proposed issue of debt securities,
      Computershare Trust Company, National Association hereby consents that reports of examinations by Federal, State, Territorial or District authorities may be furnished by such authorities to the Securities and Exchange Commission upon request
      therefore.</div>
    <div><br>
    </div>
    <table id="zfa9adf593dc841519cd0e0c8d44cfea5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: middle;" colspan="2">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION</div>
            <div><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> </font>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
          </td>
          <td style="width: 46.58%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;">/s/ Scot Sandhoefner</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 3%; vertical-align: middle;">&#160;</td>
          <td style="width: 46.58%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title:&#160; Vice President</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: middle;">&#160;May 19, 2023 </td>
          <td rowspan="1" style="width: 3%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 46.58%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT 7</u></div>
    <div>
      <div>
        <div>&#160;</div>
        <div>
          <div style="text-align: center;">Consolidated Report of Condition of</div>
          <div>&#160;</div>
        </div>
        <div style="text-align: center;">COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION</div>
        <div>&#160;</div>
        <div style="text-align: center;">150 Royall Street, Canton, MA 02021</div>
        <div style="text-align: center;">at the close of business December 31, 2022.</div>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="vertical-align: top;" valign="bottom">
                <div style="margin-right: 26.1pt; font-weight: bold;">ASSETS</div>
              </td>
              <td style="vertical-align: bottom;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: top;" colspan="2" valign="bottom">
                <div style="text-align: center;">Dollar Amounts In Thousands</div>
              </td>
              <td style="vertical-align: bottom;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top;" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: top;" colspan="2" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top;" valign="bottom">
                <div>Cash and balances due from depository institutions:</div>
              </td>
              <td style="vertical-align: bottom;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: top;" colspan="2" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Noninterest&#8209;bearing balances and currency and coin</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell" valign="bottom">
                <div>3,297</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">Interest&#8209;bearing balances</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>354,504</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Securities:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">Held-to-maturity securities</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div style="margin-left: 9pt;">Available-for-sale securities</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Federal funds sold and securities purchased under agreements to resell:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>&#160;&#160;&#160;Federal funds sold in domestic offices</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>&#160;&#160;&#160;Securities purchased under agreements to resell:<br>
                </div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">-0-<br>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Loans and lease financing receivables:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">Loans and leases held for sale</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;">Loans and leases, net of unearned income</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">LESS: Allowance for loan and lease losses</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;">Loans and leases, net of unearned income and allowance</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">-0-<br>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Trading assets</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Premises and fixed assets (including capitalized leases)</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>7,524</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Other real estate owned</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Investments in unconsolidated subsidiaries and associated companies</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Direct and indirect investments in real estate ventures</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Intangible assets:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>&#160;&#160;&#160;Goodwill</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>671,815</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#160;&#160;&#160;Other intangible assets</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Other assets</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="border-bottom: 1px solid #000000; vertical-align: bottom; width: 9%; text-align: right;" colspan="1" class="cftnumcell">
                <div>139,364</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Total assets</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>1,176,504</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div style="font-weight: bold;">LIABILITIES</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Deposits:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">In domestic offices</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt;">Noninterest&#8209;bearing</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">Interest&#8209;bearing</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Federal funds purchased and securities sold under agreements to repurchase:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>&#160;&#160;&#160;Federal funds purchased in domestic offices</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#160;&#160;&#160;Securities sold under agreements to&#160; repurchase</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Trading liabilities</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Other borrowed money:</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div style="margin-left: 9pt;">(includes mortgage indebtedness and obligations under capitalized leases)</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Not applicable</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Not applicable</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Subordinated notes and debentures</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Other liabilities</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="border-bottom: 1px solid #000000; vertical-align: bottom; width: 9%; text-align: right;" colspan="1" class="cftnumcell">
                <div>184,765</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 4px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Total liabilities</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>184,765</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div style="font-weight: bold;">EQUITY CAPITAL</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Perpetual preferred stock and related surplus</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">-0-<br>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Common stock</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>500</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Surplus (exclude all surplus related to preferred stock)</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>827,224</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Retained earnings</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>164,015</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Accumulated other comprehensive income</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Other equity capital components</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Total bank equity capital</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>991,739</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; width: 88%;" valign="bottom">
                <div>Noncontrolling (minority) interests in</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>consolidated subsidiaries</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>-0-</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 2px; width: 88%;" valign="bottom">
                <div>Total equity capital</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="border-bottom: 1px solid #000000; vertical-align: bottom; width: 9%; text-align: right;" colspan="1" class="cftnumcell">
                <div>991,739</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align: top; padding-bottom: 4px; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Total liabilities and equity capital</div>
              </td>
              <td style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
              <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell" valign="bottom">
                <div>1,176,504</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify;">I, Robert G. Marshall, Assistant Controller of the above named bank do hereby declare that this Report of Condition is true and correct to the best of my knowledge and belief.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 50%; vertical-align: top; font-style: italic;">&#160;</td>
              <td style="width: 40%; vertical-align: top; font-style: italic;">
                <div style="text-align: right;">Robert G. Marshall</div>
              </td>
              <td colspan="1" style="width: 10%; vertical-align: top; font-style: italic;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">&#160;</td>
              <td colspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: right;">Robert G. Marshall</div>
              </td>
              <td colspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: right;">Assistant Controller</div>
              </td>
              <td colspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
        <div>&#160;</div>
      </div>
    </div>
  </div>
  <br>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ny20009120x1_ex107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold; margin-left: 684pt; text-align: right;"><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: right; font-weight: bold;"> Exhibit 107</div>
      <div style="text-align: center; font-weight: bold;">Calculation of Filing Fee Tables</div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Form&#160;S-3</div>
      <div style="text-align: center;">(Form Type)</div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">INSMED INCORPORATED</div>
      <div style="text-align: center;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Table 1: Newly Registered and Carry Forward Securities</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z22aa3e5ef12e4a83a20579e6139abe6a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 7.9%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom;">&#160;</td>
            <td style="width: 10.78%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom;">&#160;</td>
            <td style="width: 9.38%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom;">&#160;</td>
            <td style="width: 7.76%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom;">&#160;</td>
            <td style="width: 7.14%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6.98%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6.98%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom;">&#160;</td>
            <td style="width: 3.62%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom;">&#160;</td>
            <td style="width: 8.28%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5.96%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5.96%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5.96%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom;">&#160;</td>
            <td style="width: 7.9%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 11.65%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 9.66%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.04%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 10.78%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Security<br>
                Type</div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 9.38%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Security Class Title</div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 7.76%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Fee<br>
                Calculation<br>
                or Carry<br>
                Forward<br>
                Rule</div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 7.14%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Amount<br>
                Registered</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Proposed<br>
                Maximum<br>
                Offering<br>
                Price Per<br>
                Unit</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Maximum<br>
                Aggregate<br>
                Offering<br>
                Price</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 3.62%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Fee<br>
                Rate</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 8.28%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Amount of<br>
                Registration<br>
                Fee</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carry<br>
                Forward</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Form<br>
                Type</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carry<br>
                Forward<br>
                File<br>
                Number</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carry<br>
                Forward<br>
                Initial<br>
                Effective<br>
                Date</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid;">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Filing Fee<br>
                Previously<br>
                Paid In<br>
                Connection<br>
                with Unsold<br>
                Securities<br>
                to be<br>
                Carried<br>
                Forward</div>
            </td>
          </tr>
          <tr>
            <td colspan="25" style="width: 100%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td colspan="25" style="width: 100%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Newly Registered Securities</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="font-style: italic;">Primary</div>
            </td>
            <td colspan="2" style="width: 11.65%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 9.66%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.04%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 10.78%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 9.38%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 7.76%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 7.14%; vertical-align: top; border-top: #000000 2px solid;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 6.98%; vertical-align: top; border-top: #000000 2px solid;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 6.98%; vertical-align: top; border-top: #000000 2px solid;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: top; border-top: #000000 2px solid;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: top; border-top: #000000 2px solid;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 5.96%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 5.96%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 5.96%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td style="width: 7.9%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid;">
              <div style="text-align: center;">Fees to </div>
              <div style="text-align: center;">Be Paid</div>
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 10.78%; vertical-align: top;">
              <div style="text-align: center;">Equity</div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 9.38%; vertical-align: top;">
              <div style="text-align: center;">Common Stock, </div>
              <div style="text-align: center;">$0.01 par value per share</div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 7.76%; vertical-align: top;">
              <div style="text-align: center;">456(b) and 457(r)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td style="width: 0.28%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 7.14%; vertical-align: top;" nowrap="nowrap">
              <div style="text-align: center;">(2)</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 6.98%; vertical-align: top;" nowrap="nowrap">
              <div style="text-align: center;">(2)</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 6.98%; vertical-align: top;" nowrap="nowrap">
              <div style="text-align: center;">(2)</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: top;" nowrap="nowrap">
              <div style="text-align: center;">(1)</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: top;" nowrap="nowrap">
              <div style="text-align: center;">(1)</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: top;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: top;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: top;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: top; border-right: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 11.65%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 9.66%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.04%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 4.05%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.71%;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 8.39%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">Fees to </div>
              <div style="text-align: center;">Be Paid</div>
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 11.65%;">
              <div style="text-align: center;">Debt</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 9.66%;">
              <div style="text-align: center;">Debt Securities</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.04%;">
              <div style="text-align: center;">456(b) and </div>
              <div style="text-align: center;">457(r)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">(2)</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">(2)</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">(2)</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 4.05%;">
              <div style="text-align: center;">(1)</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.71%;">
              <div style="text-align: center;">(1)</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-style: italic;">Secondary</div>
            </td>
            <td colspan="2" style="width: 11.65%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 9.66%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.04%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 4.05%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.71%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.39%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 11.65%;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 9.66%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.04%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 4.05%;">&#160;</td>
            <td rowspan="1" colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.71%;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td rowspan="1" colspan="2" style="width: 8.39%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">Fees to </div>
              <div style="text-align: center;">Be Paid</div>
              <div style="text-align: center;"><br>
              </div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 11.65%;">
              <div style="text-align: center;">Equity</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 9.66%;">
              <div style="text-align: center;">Common Stock, </div>
              <div style="text-align: center;">$0.01 par value per share</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.04%;">
              <div style="text-align: center;">457(c)</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">27,793</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">$18.36<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 7.42%;">
              <div style="text-align: center;">$510,279.48<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 4.05%;">
              <div style="text-align: center;">.0001102</div>
            </td>
            <td colspan="2" style="border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; vertical-align: top; width: 8.71%;">
              <div style="text-align: center;">$56.24</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.39%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 11.65%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 9.66%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.04%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div style="text-align: center;">Fees </div>
              <div style="text-align: center;">Previously</div>
              <div style="text-align: center;"> Paid</div>
            </td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 10.78%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 9.38%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 7.76%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 7.14%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 6.98%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 6.98%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 3.62%;">&#160;</td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 8.28%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td colspan="25" style="width: 100%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td colspan="25" style="width: 100%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Carry Forward Securities</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 11.65%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 9.66%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.04%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div style="text-align: center;">Carry Forward Securities</div>
            </td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 10.78%;">
              <div style="text-align: center;">Equity</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 9.38%;">
              <div style="text-align: center;">Common Stock, </div>
              <div style="text-align: center;">$0.01 par value per share</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 7.76%;">
              <div style="text-align: center;">415(a)(6)</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.28%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 7.14%;">
              <div style="text-align: center;">(4)</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 6.98%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 6.98%;">
              <div style="text-align: center;">$215,585,139</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 3.62%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.44%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 8.28%;">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.48%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 5.96%;">
              <div style="text-align: center;">424b5</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.48%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 5.96%;">
              <div style="text-align: center;">333-238560</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.48%;">&#160;</td>
            <td style="vertical-align: top; white-space: nowrap; width: 5.96%;">
              <div style="text-align: center;">February 25, 2021</div>
            </td>
            <td style="border-left: 2px solid; vertical-align: top; width: 0.48%;">&#160;</td>
            <td style="border-right: 2px solid; vertical-align: top; white-space: nowrap; width: 7.9%;">
              <div style="text-align: center;">$27,275</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="8" style="width: 36.77%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="7" style="width: 35.9%; vertical-align: bottom;" nowrap="nowrap">
              <div style="text-align: center; font-weight: bold;">Total Offering Amounts</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;" nowrap="nowrap">
              <div style="text-align: center;">$216,095,418.48</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: bottom;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: bottom;" nowrap="nowrap">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="8" style="width: 36.77%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="7" style="width: 35.9%; vertical-align: bottom;" nowrap="nowrap">
              <div style="text-align: center; font-weight: bold;">Total Fees Previously Paid</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: bottom;" nowrap="nowrap">
              <div style="text-align: center;">$27,275</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom;">&#160;</td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="8" style="width: 36.77%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="7" style="width: 35.9%; vertical-align: bottom; border-bottom: #000000 2px solid;" nowrap="nowrap">
              <div style="text-align: center; font-weight: bold;">Total Fee Offsets</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: bottom; border-bottom: #000000 2px solid;" nowrap="nowrap">
              <div style="text-align: center;">N/A</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: middle; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="8" style="width: 36.77%; vertical-align: middle; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 7.42%; vertical-align: middle; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 4.05%; vertical-align: middle; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 8.71%; vertical-align: middle; border-left: #000000 2px solid;">&#160;</td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 6.45%; vertical-align: middle; border-left: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="width: 8.39%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.9%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.87%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td colspan="7" style="width: 35.9%; vertical-align: bottom; border-bottom: #000000 2px solid;" nowrap="nowrap">
              <div style="text-align: center; font-weight: bold;">Net Fee Due</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 6.98%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 3.62%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 0.44%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            <td style="width: 8.28%; vertical-align: bottom; border-bottom: #000000 2px solid;" nowrap="nowrap">
              <div style="text-align: center;">$56.24</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 5.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 0.48%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
            <td style="width: 7.9%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2194e7b5236a49fe93402d540a73fe94" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div>(1)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div>In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, the registrant is deferring payment of the registration fees for these securities and will pay the registration fees subsequently in advance or on a
                &#8220;pay-as-you-go&#8221; basis.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 96%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div>(2)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div>An indeterminate aggregate initial offering price or principal amount of the securities of each identified class is being registered as may from time to time be offered under this registration statement at indeterminate prices, along
                with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold under this registration statement. Separate consideration may or may not be received for
                securities that are issuable upon conversion, exercise or exchange of other securities.</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div>(3)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the registrant&#8217;s common stock on the Nasdaq Global Select Market
                on May 17, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">
              <div>&#160;</div>
              <div>(4)</div>
            </td>
            <td style="width: 96%; vertical-align: top;">
              <div>&#160;</div>
              <div>Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $215,585,139 of unsold securities (the &#8220;Unsold Securities&#8221;) previously registered pursuant to the Registration
                Statement on Form S-3 (File No. 333-238560), which became automatically effective on May 21, 2020 (the &#8220;Prior Registration Statement&#8221;). In connection with the filing of the prospectus supplement, dated February 25, 2021 (the &#8220;Prospectus
                Supplement&#8221;) to the Prior Registration Statement, the registrant paid a filing fee of $27,275 associated with the offering of the Unsold Securities (based on the filing fee rate in effect at the time of the filing of the Prospectus
                Supplement). The filing fee associated with the offering of the Unsold Securities is hereby carried forward to be applied to the Unsold Securities registered hereunder, and no additional filing fee is due with respect to the Unsold
                Securities in connection with the filing of this Registration Statement. Pursuant to Rule 415(a)(6), the offering of securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this
                registration statement.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 96%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_insmed.jpg
<TEXT>
begin 644 logo_insmed.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-/@N"8K/6=1B\NXD_KIT76-.\0Z1IFNZ1<K=Z9J]C;:C87*@J)K6[A2:%BC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]G:6NGVEK86-O#:65E;P6EG:6T:0V]K:VT2PV]O!$@5(H8(42**-%"(BJJ@
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M>@E2HX?#X;#QE*:HX?#8>G2HTHN4I2G)0]I5D^>K.<M3I\-_"W@;PER*?#O
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MJ$L5Y\4/#433;FO]/\1WLT$OB^.,23-<:7XNO9[ZX M8K#Q)I%M:FUN?ZB_
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MLT445_&I^Q!7XI_\%R_^3;?A7_V7#3O_ % O'5?M97XI_P#!<O\ Y-M^%?\
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MNN_%OQ_X:^"RW]J+BV\/0Z/+\0O%MH6),<>N6%CK7AS0-.>6/9*(K3Q1JMU
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MY:^S\8/^2#S7_L(RS_U888\;A#_D>X7_ *]XG_U'J'[LT445_&I^Q!7XI_\
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MWK@%8_G(K^#(QE.4813<IR48I7;<I-))):MMNVFI^[-J*;>B2;;\DKL_A/\
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MU.*18F"L;=X)@-LJD_QS5_4-_P $/OB;9Z_\!/B1\*YIPVL_#OXACQ!%"0B
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M_P!EPT[_ -0+QU7[65^*?_!<O_DVWX5_]EPT[_U O'5?;^&__)<\-_\ 8?\
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M7;*^O[2>TTSPMXS\/R6$<-@1,MS+-XG@N$D8^4L5K,K?.Z5^0?\ PXH^+/\
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ME3 K#TX81^R3HT[TH^[7IS3O3<97<XJ4I<W-)_$W=W_,[_AQ1\6?^B[?#O\
M\)SQ+_\ %UI:9_P0C^(4LTBZS^T)X-L+<1$Q2Z9X'UO5YGFWJ!')!=:YHB1Q
M%"[&9;B5PZJGDD.9$**_2L5XC<94\/5G#.>648II_P!GY4[/F2V>!:>CZH^;
MI<.Y/*I",L'=-JZ^L8I=(]JZ?5GJWAK_ ((0>$+6Z1_&'[1_B37+(.IDMO#7
MPXTOPM=,GF0%T2^U3Q=XQA5S"MU&LC:>X62:"8Q,MO)!=%%%?#5?$[CRM+GG
IQ%BHO:U+#X&A'_P"AA:</GRW/<APSD4%99=2:_OU*]1_^!3JRE^)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo_insmedx1.jpg
<TEXT>
begin 644 logo_insmedx1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S+^V3\//$'Q4_9E^+O@?PK!/>>(=2\/VFH:586
MN\W6IW7AG7=)\4C2;5$96ENM5317TZVASMGGNHX7!1V!_D:965BK JRDJRL"
M&5@<$$'D$'@@\@\&O[?Z^%/C#_P3I_9I^,?B*_\ %E]HOB#P/XBU>Z:^UK4/
MAYJUGHL.K7C[3/=W6CZKI.O:#!=7; S7USIVE6-Q?W4D]]>RSWUQ/<R?T?X&
M^,>4^'V#S3(>(L-C)97C\<LSPN-P%&&(JX;&SP]#"XF&)H2JTISP]:CA<,Z<
MZ+G4I5*<XNC4C6YZ/\*_2[^BYQ+XV9GP]QCP1C\LAQ#D^4OA_,,JSG$U<'A\
M?E5/&XO,<#6P&+IX?$4Z6-PV*S#'1KTL4J5'$X>O3E'$T:F$5+%?S.?#WP%X
ME^*'C?PQ\/O!^GR:GXD\6:M;:1I=K&K%1).2T]W=.H(M]/TZT2?4=3O),0V.
MGVMU>7#I!!(Z_P!H&F6$.E:;I^EV[SR6^FV-I8027,TES<O#9P1V\3W%Q*S2
MSSLD:M+-(S22R%G=BS$U\Y? G]D'X$?LZRRZC\//"9;Q-<6PL[GQEXCO'UWQ
M.]MM99(+6\G2.TT>&Z#'[=#H-AI4-_B(7L<ZV]LL/TW7@^-WBK@_$K,LII9/
MA,3A<FR.EBUAZF-C"GB\9BL?+#_6:]2C2JUJ=*A"&$H0PT'4E5UK5*G(ZJI4
MOL?HE_1TS3P&R'B3$<3YE@,PXJXNQ&6/&T<IJ5J^6Y7EV3PQOU'"4<3B,-A:
MV(QE6MF6,JX^K&C##WCA:%#VBP\L3B"BL'Q#XH\.>$K!M3\3:WIFA6 +*MSJ
M=Y!:++(J-(8;99762ZN&124MK9);B3&(XV.!7@+_ +77P834?L(U+7)+;<%.
ML)H-W_9P!D"%O+<IJQ4*3,<:66,8("F7$1_G7,N(LAR>I3HYKG&6Y?6JVY*6
M*QE"C5DG]OV<YJ:IZJ]245!75Y*Y_6LZM.FTISC%O9-I/[NWGL?3E?GI_P %
M,?V8-;_:?_9MU#2?!<"W7Q#^'>M0_$+P?IV LOB)M.T[4=/USPI#-Y<K1W.L
MZ/J%Q<:5$HC2\\1:7H=G<W-I9SW%U#]S^&/&'A?QIIXU7PKKNFZ[8G8));"X
M262W=U++#>6QVW5C<%06^SWD,$X')C KI*^FR'.ZF6X[+<]RJO0K3PM:EB\+
M6ISC6P]>,7K'GIR<:E&M!RI3<)ZPG+EDG9K+%8:CCL+6PU7WJ.(IRIR<7K9[
M2BU=<T9)2B]5S)736A_GDNCQN\<B-')&S))&ZE'1T)5D=6 965@0RD @@@@$
M4VO[5?V@_P#@G5^RK^T?J%]XB\8> Y/#/C?4I1-?^//AW>IX4\1ZA.UP;BXN
MM6@6UOO#6O:A>,QCN=6U_P /:IJ[0[8XK^(1Q;/%/AM_P1X_8W^'VN0ZYJFF
M_$#XI-:LDMKI7Q)\4Z?=:'#<QRPS13S:9X/\/>#(M35#$T;V.LMJ6EW,4TT=
MW87 ,?E_U'A_''A6>"5?$X/-L/C%#W\#"A1KJ52RTHXKV]*G.FV[*I5C0G9-
MNDM%+\RJ<$9I&OR4ZN%J46]*\IS@U'O.ER2DI6^S!S7][M^6?_!'O]DS7_B)
M\8++]I'Q'IZVWPV^$UWJ$?AV2]B#_P#"5_$6?37M+.'3X)8&22P\(6VHMKU[
MJ:S0R6OB"/P[:V279.JMIG]359&@>']!\*Z-IOASPOHND^'/#VC6D5AI&A:%
MIUGI&CZ58P#;#9Z=IEA#;V5E:Q#B."VACB0?=45KU_/G&G%F)XQSNIFE>E]6
MH0I0PN!PBGS_ %?"4Y3G&,IVBIU:E2I4JU9J*7-/DC^[A!+] R;*J63X*.%A
M+VDY2=6O5:M[2K)13:5WRPC&,8PC=Z*[]Z4FRBO$?&O[0_PH\"W$EAJ7B1-3
MU2$R+-I?AZ%M8N8)(PX>&YG@9=.M+A9$$36UW?07"NZEXEC$DB)X)_:)^%/C
MNX2PTWQ$NEZI*T:0Z9XBB_L>YN'DV!(K6::1]/NYVD8Q+;6U[-<LZL5A:,H[
M_FG^M/#?U[^S/[>RGZ_S>S^J_7\-[;VFWLN7VG\;_IS?VO\ </1]M2YN3VD.
M:]N7F5[]M]_+<]OHHHKWC4**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBFAT+,@92Z!2RA@64-G:67.
M0&VMM) !VG&<&@!U%%% !1110 4444 %%?-OQS_:T^!?[.YM[3XC>,(X_$%W
M&)[7PCH-N^N^*9+9@I2[N=,M&VZ39S*2;6\UJXTVVOC',EC+<R03(GCOPO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ;P7=O/:74,5S:W4,MO<V\Z++#/!.C1S0S1N"DD4L;,DB,"KHQ5@02*^(/\
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MA04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGH]W+8:OIU]I=] [QSV6HVEQ8W<+Q2R0R)+;7,<4T;QS12Q.KH"DL<D; .C
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MF.QN,S'$RIPC@\N=:4L-A8U9M1H4:>'A1GBFI?O<1S.<YPIT%#U\7C\3F%/
M9=0525##4:%&CAZ:E)UL1R)5:KA%7G.51SC237N4[))2E4<O(Z*_JS_9U_X(
MW?L]?#K2-,U/XWM??&GQX]K!+JEI+J.I:%\.M)U'/G20Z'H^E2Z9K.L0VQ=K
M)[WQ1J5S:ZO%"E\/#6B23-90_<%S^Q!^Q]=:-_84O[-'P66R^RR6?GVWP_\
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M*5&CD574@>T?LR?\G)?L]_\ 9</A/_ZGN@5Z]_P4.\)OX+_;6_:+TAQ@WOQ
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MG54$TYN'+%IM'S^!KQPN,PN)FG*.&KT\1RK[;HR56,/+GE%1;V5[O1'Z&_\
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M)&C2\?Q_HNI>%-&MYPH/F1)XDU31+M8V!4SVL+$J5#K\*5[-^SCJT>@?M#?
M?79I)(8=%^,WPNU:6:%-\L4>F^-]#O'DB3^.1%A+(G\3 #O7[GGV%ACLCSC!
M3CS0Q65X_#RBMVJV%JT_=T;4DY7BTFU))K5(^'P-5T,=@ZT79TL50J)O;W*L
M):]UIJNJNC^]*OS>_P""J?QV;X)_LC^,;'2[K[/XJ^+L\?PJT$HR^=!8>(+6
M[G\8WYCW+,(8_"%EK&F1W<)!LM5U?292V2B/^D-?S$_\%R_B(=9^-WPB^&,$
MR2VO@7X=7_BBY6-U/D:QX_UZ6TGM9T W+/'I/@K1;Q0Y(\C48V3&^3/\<^&N
M30SOC+)\-6CSX;"U9YEB(M<RE# 0=>G"<7HX5<3&A2J)Z.%26CV?[#Q)C)8+
M)L94@[5*L8X:F]FI5Y*$FGTE&DZDXM:\T5MNOP]HHKV_]FGX;0_&#]H+X,_#
M*\A>?2_&?Q(\)Z-KJ1.L<H\-RZQ:R^)9(G;@2P:!#J4T0/WI(U4<L*_M7%8B
ME@\-B,76?+1PM"MB*LENJ5"G*K4>K2TA%O5KU/Q>E3E6JTZ4%>=6I"G!=Y3D
MHQ7S;1_4!_P2H_90TGX#? '1?B5KFDHOQ7^->D6'B?6]0NHRU[H?@N]Q?^#_
M  G9^8%>QAETV2T\1:] (8+J?6]1%CJ3747A_2/LOZDTBJJ*J(H55 554!55
M5& J@8        &!2U_ >>9QB\_S;'9OC9N6(QV(G6<7)R5&FW:CAZ;=K4L/
M24*-)65H05];L_>\#@Z. PE#"4$E3H4U!.R3G+>=227VZDW*<W_-)] HHHKR
MCJ/RM_X+(?\ )E6M_P#91/ '_I?=U_(S7]<W_!9#_DRK6_\ LHG@#_TONZ_D
M9K^N/!'_ )(RK_V.L=_Z8P1^2\:_\CE?]@=#_P!+K!7]V/[(G_)IW[,'_9O'
MP5_]5MX:K^$ZO[L?V1/^33OV8/\ LWCX*_\ JMO#5>)X]?\ (IR#_L8XK_U&
MB=O G^^8_P#[!J?_ *=/H>BBBOYB/TT**** /\][Q!_R'M;_ .POJ7_I;-61
M6OX@_P"0]K?_ &%]2_\ 2V:LBO\ 12C_  J7_7N'_I*/YXEN_5_F?T"_\$'/
M^0]^TU_V"/A/_P"EOQ"K^C.OYS/^"#G_ "'OVFO^P1\)_P#TM^(5?T9U_&GB
MY_R7^=_X,K_]5&!/V/A+_D0X+_%BO_4NL%%%%?FQ](?Y[WB#_D/:W_V%]2_]
M+9JR*U_$'_(>UO\ ["^I?^ELU9%?Z*4?X5+_ *]P_P#24?SQ+=^K_,_H"_X(
M/>'K&X\1_M*^*Y;:-M2TC1/A=X>L;QD?S8K'Q%?>.=2U6VBDWB,1SW'A;1Y;
MA"CN6M[9E>-0PE_HVK^?K_@@Y_R ?VFO^PO\)_\ TB^(5?T"U_&/BS4E/C_/
ME)MJG_9M.";NHQ64X!V79.4I3:_FDWU/V7A2*CD.!LE>7UF4G;=O%UU=^:24
M;]D@HHHK\Y/H@K_/'K_0XK_/'K^C/ #_ )JW_N@_^]D_.^/O^93_ -S_ /[I
MA7]+_P#P0H_Y)/\ '?\ [*'X;_\ 4;EK^:"OZ7_^"%'_ "2?X[_]E#\-_P#J
M-RU]]XP?\D'FO_81EG_JPPQX/"'_ "/<+_U[Q/\ ZCU#]V:***_C4_8BK?6-
MCJEC>:9J=G:ZCINHVMQ8ZAI]];PW=C?6-W"]O=V=Y:7"2075K=02207%O/&\
M,T+O'(C(S*?Y/_\ @H?_ ,$V?%?[/&OZ[\6/A!HM[XB^ .J7DE_-8Z<EWJ6K
M_">6YW2S:7KB$W%Y<^#HY0XT3Q5(\HL87@T7Q)+'J$=AJWB+^LJ@@$$$ @C!
M!Y!!Z@CN#7U_!W&>9\&9C+&8%1Q&%Q"C3Q^7U9RC1Q=*#;BU)*3HXBE>7L,1
M&$W3YIQE"I2G4IS\C.,FPV<X=4:]Z=2FW*AB().=*35GH[<].5ESTVTI634H
MRC&2_P \>BO[$_C]_P $J_V3_CG=:AKUEX9OOA'XROC-/-KWPPEM-'TR]O6B
M*Q3:KX-N[2]\+2QFX)NK]]%T_0-6U29Y9+O6&FD\Y?QN^-7_  1?_::\!33W
MGPIU/PM\;M!#GR8K"]L_ WC".%4,DD]YH/BG4DT(HF-D<>E^,-5OKE^([!&9
M4/\ 3N0^+/!^=*$*V->38N27-0S51H4E+:7)CE*6#<$_A=6K0J233]E%\RC^
M9X_A3-\$Y2A1^N4E>U3"WG.W3FH-*LG;=0C.*>G.]&_Q]KV+X3_M!_&[X&7X
MU#X2?%'QGX$8W4=Y<6&B:U<IH.I7$0*QOK/AJX:X\/:XJ D"+6-+OHL<&,US
MGQ!^%'Q.^$^IIHWQ.^'OC/X?ZG,)6M;/QAX:U?P])>Q0R&*2XT\ZI:6T>HVF
M]2$O+%[BUD&&CF=65CP%?H4X8',\+RU(83,,%7C\,XT<7A:T/22J4JD?_ D?
M/J5;#5;Q=6A6IO=.=*K"7JN6<7]S/W4^ W_!;OXF:#>:;I'[0_@/1?'GA]5A
MM[WQ=X#MH_#7C>)1N,VI76AW-X/"&O7+?*JV&GKX)ME&Y_M&0(V_?[X&?M ?
M"?\ :/\ !%OX_P#A%XLM/$VAO*;34(/+FL=:T#4T&9M)\0Z+>)%J&DZA'@O&
MMQ#]FO[8Q:AI=S?:;<6UY-_!;7OO[.?[2GQ5_9?^(-AX_P#A?K]SI\@N+)/$
MGAR:5Y/#GC31;6X,LVA>)--),-U;3127,5M>HJ:IH\MS)?:->6-\%G'Y'Q?X
M/9)FN&K8GAVC3R?-8ISIT82E'+,4U=NE4H6FL)*2LJ=3#*%*#7[RA/F<X_69
M1Q?C<+4A2S&<L9A6U&4Y)/$TE_/&>GM4M7*-2\I?9J1M:7]W=%>._ #XU>%_
MVA_@]X%^,7A /!I'C31UO9--FE$UUH>L6L\VG:_X?O)1% )KG0]:M+_3)+E(
M(H;T6RWMLIM;F!F]BK^4\3AZ^#Q%?"8FE*CB<-6JX?$49JTZ5:C.5.K3FM;2
MA.,HNS:NM&?JE.I"M3IU:4E.G5A&I3G':4)I2C)>4HM->H5_,_\ \%U_^2L_
M G_LG?B/_P!25*_I@K^9_P#X+K_\E9^!/_9._$?_ *DJ5^D^#W_)>99_V#9G
M_P"H%<^<XO\ ^1%BO^OF&_\ 4BF?A/7IOP4\+VOC?XR?"7P7?(LEEXO^)O@/
MPO>1M')*LEKK_BK2M*N$:*&6&:16ANW4QQ312."526-B''F5?0_[(G_)V/[,
M'_9P_P %?_5D^&J_KS,ZDZ.6YA6IMQG2P6+J0DMU.%"I*+3[II-'Y)A8J>)P
M\)*\9UZ,9+NI5(IKYIG]V-%%%?YZ'] A1110!_(Q_P %C_\ D]77?^R>> /_
M $WW5?E=7ZH_\%C_ /D]77?^R>> /_3?=5^5U?W;P+_R1O#'_8DR[_U&@?AF
M>?\ (YS/_L-Q'_IR1]J?\$Z?"]KXO_;:_9UTF\19(;3QU_PE"*T<D@%UX(T3
M5_&EBX6*6)@T=[H%O(LA<QQ,HEFBFA1X9/[9*_C5_P""4O\ R?U\!?\ NJ/_
M *ICXBU_957\_P#CM5F^*<KHMOV=/(*%6,>BG5S',H3:7>4:--/ORKL??<"Q
M2RO%3M[TL?.+?5J&'PSBODYRMZL****_$C[4*_AE_;6_Y.]_:9_[+A\2O_4K
MU.O[FJ_AE_;6_P"3O?VF?^RX?$K_ -2O4Z_=_ ;_ )'F>?\ 8JI?^I=,^%X[
M_P!RP/\ V%3_ /3,CYAK]K/^"&G_ "<E\5/^R'ZC_P"I[X%K\4Z_:S_@AI_R
M<E\5/^R'ZC_ZGO@6OVGQ)_Y(;B/_ + 8_P#J30/C.'/^1YEW_7]_^FYG]1E%
M%%?P^?MI_&S_ ,%6]0%_^WE\;U0QM%81_#?3XV174DP?"KP1)<"3>?FDCNYK
MB+<BJA2--H;!D?\ .VOT)_X*IV7V']O3X\(J2K'<2_#J]C:4$>;]L^$W@2>=
MXFVJ'B6Z>XB4KN"F-HV8O&QK\]J_O7@]17"7"_)\/^KV2V[ZY=AF[^=[W\[G
MX1F]WFV9\V_]H8R__A14V\NWD%%?H/\ \$L[#1]8_;D^#>BZ]HVF:]I>K6OQ
M)MY]/U>SM=0L&:U^%?C75(99K*\@N+>X:*;3T,0= 8Y2DZ.'B"M_7;_PJ'X3
M?]$O^'?_ (17AK_Y65\?QMXG4."\VH956R>MCY5\OHX^->GC:>'BHU<1BL/[
M/DEAZKO&6%D^;F5^9+E5KOU\EX9GG.$J8J&,A05/$3H.$J,JC;A3I5.;F52"
MLU5M:V\=]=/X"Z*_OT_X5#\)O^B7_#O_ ,(KPU_\K*/^%0_";_HE_P ._P#P
MBO#7_P K*^/_ .(^8/\ Z)G$_P#ASI?_ #$>O_J'6_Z&5+_PFE_\N]?Z>G\!
M=%?WZ?\ "H?A-_T2_P"'?_A%>&O_ )64?\*A^$W_ $2_X=_^$5X:_P#E91_Q
M'S!_]$SB?_#G2_\ F(/]0ZW_ $,J7_A-+_Y=Z_T]/X"Z]M_9GTV/6OVC_P!G
M[1Y;9+R+5OC;\*=-DM)"JQW4=]X[T&U>V=F9%"3K*8F+.BA6)+*.1_</_P *
MA^$W_1+_ (=_^$5X:_\ E95FS^%GPQT^[M;^P^'/@.QO[&Y@O+*]L_"'A^VN
M[.[MI5FMKJUN8=/2:WN;>9$E@GB=)8I462-E=01ABO'?"XC"XFA#AS$TY5Z%
M:C&H\RIM0E4IR@IM+!Q;Y7)2LI)NUDUN:4N!:M.K2J2S&G)0J0FX_5I+F491
MDU=U6E=)J[3Z:=N[K^,K_@J5KIU[]NSXZRK<BYM]-O/!.A6RI<?:(K4:/\.?
M"-E>6T1'RQ%-4COY+FW 'DWLMRCYD#D_V:U_#Y^WB-4'[9/[27]KD&[_ .%L
M^*S"1Y&/[+-Z3H8_T8"/*Z*=/4[AY^0?M1-UYQ/@>!%&,N)<VKMKFI9'4IQ3
M^*U;'X*4I)>7L5%OISI=3OXZFUEN$@KVEC5)OI[E"LDGZ\[:7EY'R57Z$_\
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MNN3!H4GP-"N-4AUA72-QYL;V2R0NLD4JI+%*B>^(Z2(DD;K)'(JO'(C!T='
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M3?AS.<PQV>X>.-Q=6M&K2Q$(TVU"BFJ4JJ:HTU"DI?N[<W+S/JV?O_7YV_\
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M#R-+R]NKI4;P[XD+(MQ/),J,0^"RAP"1P2..*I?\.*/BS_T7;X=_^$YXE_\
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M^'?_ (3GB7_XNBBOOO\ B(?&'_0W_P#,?E?_ ,Q'@KA_*-/]D[?\Q&*_N?\
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M?_!$GX]>%FOK_P +_%KX1>)/#EIM*7NOGQGX3UN97=(U+Z+IWAKQC8PG<QW
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E;4]G Y9@<M52."P\:"J\GM.64Y.?L^;DYI5)SD^7GE;7[3/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20009120x1_ex5-1image01.jpg
<TEXT>
begin 644 ny20009120x1_ex5-1image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Q +,# 2(  A$! Q$!_\0
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M-0CDD4DK%.54<]A0!AR_%/7UE=0EEA6('[L^OUHK@9EVS2*,\,1S]:*8'O\
M\-_]3JO_ %\FFO\ \E//_7G_ $HHI 2_#7_D%WO_ %]/52/_ )#_ (M_Z]O_
M &6BB@#A_#7_ "&[3_?%>G_$'_D4[SZ#^=%% %7Q'_R3T_\ 7"/^E<?XM_Y
M7AS_ *]C_2BBA 'PU_Y&F/\ ZY/_ "KN/B!_R T_Z^$HHH8$7B[_ %V@_P#7
MRO\ 2M_5O^0;<_[AHHI >1?#G_D=7^K5[0W0T44V!R/PV_Y!5[_U]/\ TJ+P
M/_R'O$7_ %W_ *FBB@#E;'_DI1_ZZFNO^)/_ ""[/_KZ2BB@!GQ,_P"1=@_Z
M[I_(U)XZ_P"1'/TB_F*** -6[_Y%)_\ KS_]DJMX!_Y%.Q_W3_,T44@/'IO]
+=)_O'^=%%%4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ny20009120x1_ex5-2image01.jpg
<TEXT>
begin 644 ny20009120x1_ex5-2image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !, 1@# 2(  A$! Q$!_\0
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M +S* O\ P+%</^U(Z7GC;X;:-K4S0^&KN^+79W[4<AXU.X]L*QY[!R:]CO/
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M$ E0.6&[*Y'=6'4&II/"6D2:TNK&V"Z@MV+P3J &#B#R ,X^[L_AZ9YJE9^
M=!LH)(K2WDA6:"."?;(<S;'WJSGNP;<=W^VWK0!-)XWT*.2 ->?NIKV/3XYP
MN8VED@6=/F'&UD=<-TR0*;'XUTV;4M-LK>&]GDOX(KE&CARJ1R,54N<\<JWK
MTH@\">'X(;J!+(&UN;N6\EMV;,9>2'RG&.R[?X>@[4RV\"Z3:WFE7-LUS')I
MMM#:0Y=7S'$25#%E)S\QR003F@!TGCG2%TK4=0C^US6UC<K:.4@;YY6E\H*F
M< G><'TZ]""9(_&FD2:?]L5Y_)^QW-\<PE6$=NP24$'N&./?MQ4%UX$TBZ35
M!<-=R/J#0M+(\@9AY,OFQ@9'(#?WL\<=*'\!:,^EP6'^E)#%'<0DQS%&DCG8
M-,C8XVL0#@8QCC% %B'QAIDFMC3&6[CD:184G> B%Y#!Y^P/T#>7\W..GK5O
MP[XCL/$"/)IWV@Q!5DCDEA9%EC;[KH2.5../;!Z$$UQX/T4>(3KBV:+J9<LT
MZ@!F4PK$8SQRFU%.WU&?6F^&_!^E^'KQKFP^T&3[.MI'YLN_RH5/RQCN0. ,
MY. !F@#HJ*** .9\0>)8-$\6:-9ZA=P6MC>VMT=TO&Z9)+<1J#ZXDDX[_A7.
M6?BS79?$/V=_(;=+>QSZ>MHZR6,<0?R9FD)PP?:@Z 'S!MX4Y](9U4J&8 L<
M+DXR?04F]0S LN5&XC/0>OZ'\J /'O\ A//$G]@7+ZDL>E75O;Z0TET8-T.+
MFZV2SIGJHB.2I^ZRL.0,G8;Q9K3Z+I\L]W:V5M-=3PMK+63F)XT&8F$1;*[^
M1DD@[3C[ZUZ2KHQPK*> W!SP>A_2HOMEM^\_TF']W]_YQ\O;GTH \KU3QQXK
MM+!+MM*4(='MYYT2%O,M[B5Y5$FT\^7\@W*?F7<"> U>MTT2(8U<.NQL;6SP
M<]/SH,B D%U!! (STST_.@#B9/&,D&K>+],5H;C5K#+Z9I_22X46D<N!W.7+
MC/X=JR8_%FM?V-K,UK?Z??QVRVKPZBUH]O%ND=A-"06(W(J@@D@ N Y&":]*
M,\09U,L89!N<;AE1ZGTI^]2Y0,-P&2N>0/7]#0!RVH>)+BV^'JZW#;RSZA-:
MQFWMS 4:2>3"HNS<V,NPR S8&>3UKF_^$R\1?8-!FBT]I;F-+H:M:-;E)F\G
M8-T:Y.&(<2!,G(.W.3FO21<P&)I!-'Y:G#/N& ?<U(K!E#*05(R"#D&@#RNT
M\<:V/^$=>]5(_M5CI\S0K:%GO))^)=A+*%"<?*,L,[B,<&&V\;:KCQE)+J4)
MFTO[9Y-IY<>8UCN&1&(!WGY0.H .[/I7K3.J8WL%R<#)QD^E1BXA,YA$T9F'
M6/<-WY4 ><^+?&^-7\/?V)K=K%I5\LQ>X41.KLDD:X!<C^\W YK<\.Z_?WGC
M+6-+O#"T$&YX/(B.$5650'8MD.<YP4P0"58@&NK2>%U+)+&RAMA(8$!O3Z\B
MG"1"VT.I/(QGTZT 9GBR\N-.\+:Q>V6/M5M933197<-ZH2O'?D"O-M8\;^)+
M32]1^VQQZ9=V<UC!)+Y2F,^87WRQLYP48!2,GY<D'D&O7J:TB*Q#.H*KN()Z
M#U^E 'F6K>+/$%G8Z3)I035?[0LUN(Y5B4J# 3)<*2AQF2/")@X#<UUNDW6J
MZOX-^VV\D=OJ%Y&]Q:&6([8T9BT(=>OW"@;OG/2N@\Q,,=ZX49//0>M!D0'!
M=0=I;!/8=3].10!YK/XKUQ]*T6^N;BVT6VU99;G[1+:M<): *GDVYP5RSY=B
M3W4J.2IJ ^+O%!UG1#-:&TAN+/3'N[=[<&.&6XEE67>Y8.F!& O#?,5# 9KU
M#S8]ZIO7>PW*N>2/44JR(Q&UU.02,'KCK0!PW@3Q)JVL:S>6^L1_98XGNEM1
MY8_TM8[J2/>#GC8JQC;P3NW'@C'5>)+J:Q\.ZI=VN/M%O:RRQY&?F5"1QWY%
M7UD1E4JZD,< @]33J /++CQ5XOL?"5JSZ=)=:Y=S*]M&MLI=K=8U=VD2-V4
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MHD501@H1AW (!S71W'A$7-]+=RR0)>RZ6;%KV*%4F$I&TRK@<<=.?;I7644
M>7Q_#::;3KVVGBTFRAN(;*U>VT]7CCF2"<2-(QP"'9<J ,E?[QZCK?!.A7N@
MVFH1:C?"_EN+QITG(P[)L15W]B^$Y(X)YXS@='10 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ny20009120x1_ex5-2image02.jpg
<TEXT>
begin 644 ny20009120x1_ex5-2image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !1 *P# 2(  A$! Q$!_\0
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M=T1W+QSWP:AE\7FRU+45NK2^8)/I\"6Y$0,9N6"#D-SACSDGVXH [.BN+O\
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ny20009120x1_ex25-1image01.jpg
<TEXT>
begin 644 ny20009120x1_ex25-1image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $  2,# 2(  A$! Q$!_\0
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MDHD)%NRW.8G4*-^2C2,%.00O"\<JZU^?X*X[/3SM^-_\CZ&^P^-_^AA\-_\
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M,(J\$@9+;F.!SQ6M111TL'F%%%% !1110 4444 %%%% !1110 4444 %%%%
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M\JQ*Q-TQ7"*S[MR@9;U +9QD5Y59^&V@U3P[X:NX;S3+J^#+JA-R8XYU$K[
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M\PM)\ ,4CB;<S @E7<E>6'0&NGT?PM?^(O!NFZ5XPL3IUQIKHL,\$RM*RJN
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M9$M45O+ST#$L.?:O)+NSU'5/'5[HOB7^T]8E@N0F\,S+;V[G:9EC0\-\T3#
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M24G9/J]^F[[G'>)]6U>2]G75YM1U>TO-.BU&TMG9EB ;8Q,BQ,ORJHE&1CD
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MWL82 S  G<S'A5^4\_7 .*\HN+_4]?\ %36.D/#=>+ 989=6566"PAY_=1$
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MO3].LM-A,.G6=M:0D[BD$2QKGUP!6;Q6'B^:$-?E_E?\3583$S7+4FK?-O\
M.WX'C7A_PYXW:V^R:7I6G>&+6XP9;T-ONGC(Z,VYFW=^B<_W>:[#PQ\*]#T6
M^2_NGGU2^"\M=[63?_?"XZ^F2<?K7?T5C4QU6=TM+]NOJ]S>EE]&G9R]ZVU^
GGHM@HHHKB.X**** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ny20009120x1_ex25-1image02.jpg
<TEXT>
begin 644 ny20009120x1_ex25-1image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !: $P# 2(  A$! Q$!_\0
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35'<UHT45BVV[LM*VP4444@/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
